Quest, Quest Diagnostics, the associated logo, NicholsInstitute, and all associated Quest Diagnostics marksare the trademarks of Quest Diagnostics. All othermarks are the property of their respective owners.

© 2004 Quest Diagnostics Incorporated.All rights reserved.

www.questdiagnostics.com HS0001-1 07/2004

rethink the possibilities

NICHOLS INSTITUTESAN JUANCAPISTRANO, CA

PediatricEndocrinology

Reference Guide

33608 Ortega HighwaySan Juan Capistrano, CA 92690949-728-4000800-642-4657

PediatricEndocrinology

Reference Guide

To our Pediatric Endocrinology colleagues,

Provided for you in this Pocket Guide are pediatricand adult reference ranges for a selection of theendocrine tests performed at Quest DiagnosticsNichols Institute. These reference ranges representthe hard work of our Clinical Correlations staff andour scientists and physicians, including those of uswho have been or continue to be practicing pediatricendocrinologists. It is our hope that this booklet willbe a convenient quick reference source to help youin your daily practice of pediatric endocrinology.

The complete endocrine test menu (includingadditional molecular endocrinology and gaschromatography/mass spectrometry testing) andmore extensive normative data will be available laterthis year in the revised edition of the Pediatric andAdult Endocrinology Manual. In addition, we urgeyou to consult the Nichols Institute Directory ofServices for information on testing in otherspecialty areas germane to your clinical practice,including molecular genetics, cytogenetics,biochemical genetics, metabolism/cardiovascular,and immunology (e.g., testing for celiac disease orother gastrointestinal disorders).

As always, we welcome your comments andsuggestions for future improvements.

Sincerely,

Jon Nakamoto, M.D., Ph.D.Managing Director

Delbert A. Fisher, M.D.Vice-President, Science and Innovation

Table of Contents

Test Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85

Numerical Index . . . . . . . . . . . . . . . . . . . . . . . . . 89

Alphabetical Index . . . . . . . . . . . . . . . . . . . . . . . 93

6

7

ACTH, Plasma 21410PThis highly sensitive assay is able to differentiate lowlevels seen in some Cushing’s syndrome patients fromnormals. It is recommended for most ACTHdeterminations.Preferred Specimen:1.5 mL plasma(0.3 mL minimum; pediatric absolute minimum 0.25 mL).Reference Range:Adults 7-10 AM: 9-52 pg/mLMetyrapone Stimulated: 112-466 pg/mLDexamethasone Suppressed: 2-8 pg/mLFemales on Oral Contraceptives: 5-29 pg/mLPediatric Prepubertal: 7-28 pg/mLPubertal: 2-49 pg/mL

Aldosterone, 24-Hour Urine 7062NPreferred Specimen:5 mL urine (0.8 mL minimum).Reference Range:Random Sodium DietAge µg/24-hours2-7 years 5.7 or less8-11 years 10.2 or less12-16 years 15.6 or lessAdults 2.3-21.0Post-Florinef™ orIV saline suppression: 5 µg/24-hours or less

8

Aldosterone, Serum 17632PMethodology:Extraction, column chromatography, RIAPreferred Specimen:2 mL serum(0.6 mL minimum; pediatric absolute minimum 0.25 mLor lower if sample may be diluted).Reference Range:Males and Females(random sodium diet)

Upright Supine8-10 AM 3-35 ng/dL 2-9 ng/dL4-6 PM 2-21 ng/dL 2-9 ng/dLPregnancy1st Trimester 43 ng/dL or Less2nd and 3rd Trimester 120 ng/dL or LessPost-Florinef™ Suppressionor I.V Saline Infusion 4 ng/dL or LessPost-ACTH Stimulation 60 MinutesMales and PremenopausalFemales (Follicular Phase) 5-20 ng/dLPediatric Reference Rangesfor Aldosterone, SerumPremature Infants (31-35 Weeks) 144 ng/dL or LessTerm Infants, 3 days old 217 ng/dL or Less

ACTH Stimulation Baseline 60 Minutes

1-12 Months 2-70 ng/dL 5-170 ng/dL1-5 Years 2-37 ng/dL 13-85 ng/dL6-12 Years 3-21 ng/dL 14-50 ng/dLTanner Stages II-IIIMales 1-13 ng/dL 10-33 ng/dLFemales 2-20 ng/dL 12-31 ng/dLTanner Stages IV-VMales 3-14 ng/dL 13-30 ng/dLFemales 4-32 ng/dL 10-34 ng/dL

9

Alkaline Phosphatase,Bone Specific 17772PPreferred Specimen:1 mL serum(0.3 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males 8.8 - 30.0 µg/LFemales 5.7 - 22.0 µg/LPediatric2-24 Months 25.4 - 124.0 µg/L2-9 Years 24.2 - 89.5 µg/LTanner Stages I-II 19.5 - 87.5 µg/LTanner Stages III-IV 19.5 - 156.0 µg/L

Alpha Subunit 127282PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Preferred Specimen:2 mL serum(0.3 mL minimum; pediatric absolute minimum 0.125 mL).Reference Range:< 1.0 ng/mLMid-cycle Peak andPostmenopausal Women: Less than 3.6 ng/mLHypothyroids(Male and Female): Less than 2.5 ng/mLPregnant orhCG Producing Tumors: Varies with

Concentration of hCG

10

3a-Androstanediol Glucuronide(3-Alpha Diol G) 16808PPreferred Specimen:2 mL serum (0.3 mL minimum).Reference Range:Males 260-1500 ng/dLFemales 60-300 ng/dLPediatricPrepubertal 10-60 ng/dLFemalesTanner Stages II-III 33-244 ng/dLMalesTanner Stages II-III 19-164 ng/dL

Androstenedione, Serum 18549PMethodology:Extraction, RIAPreferred Specimen:2 mL serum(0.5 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males and Premenopausal Females 50-250 ng/dLPostmenopausal Females 16-120 ng/dL

Post-ACTH Stimulation 60 MinutesMales and PremenopausalFemales (Follicular Phase) 72-290 ng/dLPremature Infants (31-35 Weeks) 480 ng/dL or LessTerm Infants, 3 days old 290 ng/dL or Less

ACTH Stimulation Baseline 60 Minutes

1-12 Months 6-78 ng/dL 21-140 ng/dL1-5 Years 5-51 ng/dL 12-68 ng/dL6-12 Years 7-68 ng/dL 12-98 ng/dLTanner Stages II-IIIMales 17-82 ng/dL 29-88 ng/dLFemales 43-180 ng/dL 58-230 ng/dLTanner Stages IV-VMales 57-150 ng/dL 78-215 ng/dLFemales 73-220 ng/dL 91-320 ng/dL

11

Angiotensin ConvertingEnzyme (ACE) 18572PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Pediatric range:6 Months-17 Years: 13-100 U/LAdult range: 9-67 U/L

CAH Panel 11, Neonatal,Random Urine 10046NPreferred Specimen:7 mL frozen urine (2.1 mL minimum).Collect spot urine. Urine can be collected directly fromdiaper. DO NOT USE PRESERVATIVES.After collection, mix thoroughly, aliquot and store frozen.Ship sample frozen.Reference Range:denominator =

tetrahydrocortisone + alpha and beta cortolone21-Hydroxylase Deficiency(21-1) 15β,17α-(OH)2-pregnanolone x 100/denominator1 DAY: 3.8-17.42-4 DAYS: 1.0-14.4>16 DAYS: 1.0-2.6(21-2) 17α-OH-pregnanolone x 100/denominator1 DAY: 2.0-22.02-4 DAYS: 1.0-11.0>16 DAYS: 1.0-4.0(21-3) Pregnanetriol x 100/denominator1 DAY: 2.0-30.02-4 DAYS: 1.0-13.0>16 DAYS: ≤3.0(21-4) Pregnanetriolone x 100/denominator1 DAY: 0.7-15.92-4 DAYS: ≤14.5>16 DAYS: ≤0.217-Hydroxylase Deficiency(17-1) 5α-tetrahydro-11-dehydrocorticosterone

x 100/denominator1 DAY: ≤8.02-4 DAYS: ≤11.0>16 DAYS: ≤34.3

12

(17-2) 6α-OH-tetrahydro-11-dehydrocorticosteronex 100/ denominator

1 DAY: 1.0-28.02-4 DAYS: 1.0-11.0>16 DAYS: 1.0-2.0(17-3) 16α-OH-pregnenolone x 100/16α-OH-DHEA1 DAY: 0.33-1.333-4 DAYS: 0.10-2.16>16 DAYS: 0.17-0.6611B-Hydroxylase Deficiency(11-1) Tetrahydro-11-deoxycortisol x 100/denominator1 DAY: 2.9-25.02-4 DAYS: 1.1-26.0>16 DAYS: 0.5-1.4(11-2) 6α-OH-tetrahydro-11-deoxycortisol

x 100/denominator1 DAY: ≤13.02-4 DAYS: ≤11.1>16 DAYS: UNDETECTABLE3B-OL-Dehydrogenase Deficiency(3-1) Pregnenetriol x 100/denominator1 DAY: ≤24.42-4 DAYS: ≤17.1>16 DAYS: 0.5-2.4(3-2) Pregnenetriol/Pregnanetriolone1 DAY: 0.1-10.82-4 DAYS: 0.2-95.2>16 DAYS: 5.6-28.6Individual Steroids 17α-OH-Pregnanolone1 DAY: 30-420 µg/g Creat2-4 DAYS: 15-200 µg/g Creat>16 DAYS: 40-90 µg/g Creat15B,17α-(OH)2-Pregnanolone1 DAY: 85-490 µg/g Creat2-4 DAYS: 25-270 µg/g Creat>16 DAYS: 45-80 µg/g Creat16α-OH-DHEA1 DAY: 500-220000 µg/g Creat2-4 DAYS: 2000-180000 µg/g Creat>16 DAYS: 200-16650 µg/g CreatPregnanetriol1 DAY: 45-620 µg/g Creat2-4 DAYS: 20-280 µg/g Creat>16 DAYS: 5-70 µg/g Creat

13

Tetrahydro-11-Deoxycortisol1 DAY: 70-670 µg/g Creat2-4 DAYS: 30-470 µg/g Creat>16 DAYS: 15-60 µg/g CreatPregnanetriolone1 DAY: 20-280 µg/g Creat2-4 DAYS: ≤260 µg/g Creat>16 DAYS: ≤10 µg/g Creat16a-OH-pregnenolone1 DAY: 4400-98900 µg/g Creat2-4 DAYS: 3460-150840 µg/g Creat>16 DAYS: 75-10910 µg/g CreatPregnenetriol1 DAY: ≤360 µg/g Creat2-4 DAYS: ≤390 µg/g Creat>16 DAYS: 20-180 µg/g CreatTetrahydrocortisone1 DAY: 620-13160 µg/g Creat2-4 DAYS: 530-7430 µg/g Creat>16 DAYS: 1600-5570 µg/g Creat6α-OH-Tetrahydro-11-deoxycortisol1 DAY: ≤120 µg/g Creat2-4 DAYS: ≤170 µg/g Creat>16 DAYS: <40 µg/g CreatTetrahydro-11- 5α-Tetrahydro-11-

Dehydrocorticosterone1 DAY: ≤130 µg/g Creat2-4 DAYS: ≤255 µg/g Creat>16 DAYS: 230-1130 µg/g Creata-Cortolone1 DAY: 25-520 µg/g Creat2-4 DAYS: 20-380 µg/g Creat>16 DAYS: 40-600 µg/g Creat18-OH-Tetrahydro-11-B-Cortolone1 DAY: 120-1360 µg/g Creat2-4 DAYS: 150-1175 µg/g Creat>16 DAYS: 170-1350 µg/g Creat6α-OH-Tetrahydro-11-Dehydrocorticosterone1 DAY: 30-540 µg/g Creat2-4 DAYS: 20-250 µg/g Creat>16 DAYS: 10-100 µg/g Creat* Note: Prior to 16 days of age, measurement of thissteroid is compromised by interference from other fetalsteroids.

14

Calcitonin 19927PMethodology:ICMAPreferred Specimen:1 mL serum (0.3 mL minimum).Reference Range:Calcitonin, SerumAdults Basal pg/mLFemales: < 4 pg/mLMales: < 8 pg/mLPost Calcium stimulation:Females: 2 Minutes 35 pg/mL or less

5 Minutes 25 pg/mL or less10 Minutes 20 pg/mL or less

Males: 2 Minutes 15-205 pg/mL5 Minutes 10-125 pg/mL

10 Minutes 4-125 pg/mL

15

Catecholamines, Fractionated,24-Hour Urine 4168NIncludes Epinephrine, Norepinephrine, Dopamine, Totaland Catecholamines (calculated).Preferred Specimen:10 mL urine (4.5 mL minimum).Reference Range:EpinephrineAge µg/24-hours3-8 1-79-12 8 or less13-17 11 or lessAdults 2-24NorepinephrineAge µg/24-hours3-8 5-419-12 5-5013-17 12-88Adults 15-100DopamineAge µg/24-hours3-8 80-3789-12 51-47413-17 51-645Adults 52-480Total (N+E)Age µg/24-hours3-8 9-519-12 9-7113-17 13-90Adults 26-121

16

Catecholamines, Fractionated,Plasma 8193NIncludes Epinephrine, Norepinephrine, Dopamine, andTotal Catecholamines.Preferred Specimen:4 mL plasma (2.5 mL minimum).Reference Range:EpinephrineSupine: < 50 pg/mLUpright: < 95 pg/mLNorepinephrineSupine: 112-658 pg/mLUpright: 217-1109 pg/mLDopamineSupine: < 10 pg/mLUpright: < 20 pg/mLTotal (N+E)Supine: 123-671 pg/mLUpright: 242-1125 pg/mLPediatric Reference Ranges for Catecholamines, Plasma:Due to stress, plasma catecholamine levels are generallyunreliable in infants and small children. Urinarycatecholamine assays are more reliable.Epinephrine 3-15 YearsSupine: ≤464 pg/mLUpright: Not AvailableNorepinephrine 3-15 YearsSupine: ≤1251 pg/mLUpright: Not AvailableDopamine 3-15 YearsSupine: <60 pg/mLUpright: Not Available

Catecholamines, Fractionated,Random Urine 41780NIncludes Epinephrine, Norepinephrine, Dopamine,Total Catecholamines, and creatinine.Preferred Specimen:10 mL urine (4 mL minimum).

17

Reference Range:EpinephrineAge µg/g creatinineBirth-6 Months 2-457-11 Months 5-451-2 Years 1-493-8 Years 4-329-12 Years 1-1513-17 Years 1-10Adults 2-16NorepinephrineAge µg/g creatinineBirth-6 Months 12-2867-11 Months 19-2501-2 Years 25-2103-8 Years 20-1089-12 Years 20- 7313-17 Years 15- 58Adults 7- 65Total N + EAge µg/g creatinineBirth-6 Months 24-3227-11 Months 10-2951-2 Years 30-2633-8 Years 30-1309-12 Years 25- 9013-17 Years 20- 70Adults 9- 74DopamineAge µg/g creatinineBirth-6 Months 107-21807-11 Months 96-24411-2 Years 86-18613-8 Years 295-11239-12 Years 164- 74413-17 Years 156- 551Adults 40- 390Creatinine, Random UrineAge g/L0-6 Months 0.02-0.327-11 Months 0.02-0.361-2 Years 0.02-1.283-8 Years 0.02-1.499-12 Years 0.02-1.83Adults 0.27-3.00

18

Chromogranin A 98111PPreferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:6.0-39.0 ng/mL

Collagen Cross-LinkedN-Telopeptide (NTx),24-Hour Urine 86959NIncludes Creatinine.Preferred Specimen:2 mL urine (1 mL minimum).Reference Range:Adult Females:Premenopausal: 11-48 nmol BCE/mmol creatinineAdult Males: 7-68 nmol BCE/mmol creatinineResults are primarily used for monitoring the response totherapy.A value within the premenopausal reference range doesnot rule out osteoporosis nor the need for therapy. Earlypostmenopausal women (<3 years postmenopausal) withvalues 67 nmol BCE/ mmol creatinine or greaterexperience the greatest benefit from estrogen replacementtherapy*. A decline in N-telopeptide values of 30% orgreater following 6 months of estrogen replacementtherapy is indicative of a positive therapeutic response inpostmenopausal women. Bone mineral density wasmaintained or increased at 1 year in 88% of patients with aN-telopeptide decline of 30% or greater*. * Chestnut CH, Bell NH, Clark GE et al., Hormone

replacement therapy in postmenopausal women: urinaryN-telopeptide of type I collagen monitors therapeutic effectand predicts response of bone mineral density. Am. J.Med. 102: 29-37, 1997.

Units of measure: nmol BCE/mmol creatinineAge g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

19

Collagen Cross-LinkedN-Telopeptide (NTx), Urine 9191NIncludes Creatinine.Preferred Specimen:2 mL second void urine (1 mL minimum).Reference Range:Adults:Females,premenopausal 14-76 nmol BCE/mmol CreatinineMales ≤85 nmol BCE/mmol CreatininePediatric: Females Males

nmol nmolAge BCE/mmol BCE/mmol

Creatinine Creatinine<12 Months 455-2979 300-292412-23 Months 249-1382 71-16762-5 Years 153-859 224-9476-10 Years 96-617 135-66311-14 Years 58-866 91-111515-17 Years 31-664 20-678Results are primarily used for monitoring the response totherapy. A value within the premenopausal reference rangedoes not rule out osteoporosis nor the need for therapy.Early postmenopausal women (<3 years postmenopausal)with values 67 nmol BCE/ mmol creatinine or greaterexperience the greatest benefit from estrogen replacementtherapy*. A decline in N-telopeptide values of 30% orgreater following 6 months of estrogen replacementtherapy is indicative of a positive therapeutic response inpostmenopausal women. Bone mineral density wasmaintained or increased at 1 year in 88% of patients with aN-telopeptide decline of 30% or greater*. * Chestnut CH, Bell NH, Clark GE et al., Hormone

replacement therapy in postmenopausal women: urinaryN-telopeptide of type I collagen monitors therapeutic effectand predicts response of bone mineral density. Am. J.Med. 102: 29-37, 1997.

Creatinine, Random Urine:Age g/L0-6 Months 0.02-0.327-11 Months 0.02-0.361-2 Years 0.02-1.283-8 Years 0.02-1.499-12 Years 0.02-1.83Adults 0.27-3.00

20

Corticosterone 21394PMethodology:Extraction, column chromatography, RIAPreferred Specimen:1 mL serum(0.3 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males and Females:8-10 a.m. 100-700 ng/dL4- 6 p.m. 40-260 ng/dLPediatric ng/dL:ACTH Stimulation

Baseline 60 Minutes<1 yearMales 78-1750 2260-6540Females 89-1200 2230-49001-5 yearsMales 120-1290 2160-7565Females 160-2040 2900-53206-12 yearsMales 235-1370 3360-7565Females 155-1100 1780-4970Tanner Stage II-IIIMales 115-1220 1475-4510Females 110- 600 2260-4730Tanner Stage IV-VMales 165-840 1790-5065Females 160-390 1725-5110

Cortisol Binding Globulin(Transcortin) 30338PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Adult: 19-45 mg/LPreterm Infants <8 days: 6-26 mg/L

21

Cortisol, Serum 11281XMethodology:Liquid chromatography/tandem mass spectrometryPreferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.1 mL).Reference Range:Males and Females8-10 a.m. 8-24 µg/dL4-6 p.m. 2-17 µg/dLPost-ACTH Stimulation, AMMales and Premenopausal Females(Follicular Phase): 14-41 µg/dL60 minutesPediatricPremature Infants(31-35 Weeks): 15 or Less µg/dLTerm Infants, 3 days old: 14 or Less µg/dLACTH Stimulation

Baseline 60 Minutes1-12 Months 3-23 µg/dL 32-60 µg/dL1-5 Years 6-25 µg/dL 22-40 µg/dL6-12 Years 3-15 µg/dL 17-28 µg/dLTanner Stages II-IIIMales 4-13 µg/dL 15-45 µg/dLFemales 4-16 µg/dL 16-32 µg/dLTanner Stages IV-VMales 5-15 µg/dL 18-27 µg/dLFemales 6-15 µg/dL 18-35 µg/dL

22

Cortisol, Free,Serum or Plasma 21469PPreferred Specimen:2 mL serum (0.7 mL minimum).Reference Range:

Baseline 60 minutes8-10 AM: 0.40-1.92 µg/dL 1.88-4.73 µg/dL4-6 PM: 0.20-0.90 µg/dLFull Term Newborns ≤9.3 µg/dLPremature Newborns (27-36 Weeks) ≤7.5 µg/dLFull-Term Infants, 3 Months Old ≤3.9 µg/dLPremature Infants, 3 Months Old ≤3.5 µg/dLAge Ranges (AM)6- 9 Years 0.37-1.62 µg/dL10-11 Years 0.27-1.12 µg/dL12-14 Years 0.23-1.67 µg/dL15-17 Years 0.43-1.77 µg/dL

Cortisol, Free,24-Hour Urine 11280XMethodology:Liquid chromatography/tandem mass spectrometryPreferred Specimen:2 mL urine (0.5 mL minimum).Reference Range:Cortisol adults: 2.9-34.0 µg/24-hours1-4.9 years observed range (n=6) 0.9 - 8.2 ug/24-hours5-9.9 years (+/- 2 SD range) 1.0-30.0 ug/24-hours10-13.9 years 1.0 - 45.0 ug/24-hours14-17.9 years 3.0 - 55.0 ug/24-hours

23

Cortisone, Serum 141598PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been cleared orapproved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Methodology:Liquid chromatography/tandem mass spectrometryPreferred Specimen:4 mL serum(1 mL minimum; pediatric absolute minimum 0.3 mL).Reference Range:Males and Females:0.7-2.7 µg/dL a.m.0.6-2.3 µg/dL p.m.Pediatric a.m.Full Term Infants, birth: 2.6-15.6 µg/dL7 Days: 0.3-4.5 µg/dL2 Weeks-3 Months: 0.9-5.4 µg/dL3 Months-1 Year: 0.7-4.6 µg/dL1-3 Years: 0.3-2.7 µg/dL3-5 Years: 0.5-2.5 µg/dL5-7 Years: 0.7-2.7 µg/dL7-11 Years: 0.7-3.8 µg/dL11-15 Years: 0.2-4.5 µg/dL

C-Peptide 19869PPreferred Specimen:2 mL serum (0.4 mL minimum).Reference Range:0.6-3.2 ng/mL

C-Peptide, 24-Hour Urine 8573NPreferred Specimen:2 mL urine (0.5 mL minimum).Reference Range:C-Peptide: 10.8-107.9 µg/g creat

24

Cyclic AdenosineMonophosphate (Cyclic AMP),Plasma 17269PPreferred Specimen:3.1 mL plasma (1 mL minimum).Reference Range:3.9-13.1 nmol/L

Cyclic AdenosineMonophosphate (Cyclic AMP),Random Urine 68684PPreferred Specimen:1 mL urine (0.2 mL minimum).Reference Range:Adults: 0.8-7.5 µmol/L

Deoxycorticosterone 16568PMethodology:Extraction, column chromatography, RIAPreferred Specimen:3 mL serum (1.1 mL minimum).Reference Range:Male 3.5-11.5 ng/dLFemaleFollicular 1.5- 8.5 ng/dLLuteal 3.5-13.0 ng/dLPregnancy1st Trimester 5-25 ng/dL2nd Trimester 10-75 ng/dL3rd Trimester 30-110 ng/dLPost-ACTH Stimulation 60 MinutesMales and PremenopausalFemales (Follicular Phase) 14-33 ng/dL

25

Pediatric Reference Ranges for Deoxycorticosterone, SerumACTH Stimulation

Baseline 60 Minutes<1 Year 7-57 ng/dL 20-160 ng/dL1-5 Years 4-49 ng/dL 26-140 ng/dL6-12 Years Males 9-34 ng/dL 33-140 ng/dL Females 2-13 ng/dL 19-61 ng/dLTanner Stages II-IIIMales 4-30 ng/dL 12-74 ng/dLFemales 2-12 ng/dL 13-63 ng/dLTanner Stages IV-VMales 5-14 ng/dL 19-46 ng/dLFemales 5-10 ng/dL 23-40 ng/dL

11-Deoxycortisol(Compound S) 16576PMethodology:Extraction, column chromatography, RIAPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Adults: 20-130 ng/dLPost-Metyrapone >5000 ng/dL = 5µg/dLPost-ACTH Stimulation 60 MinutesMales and PremenopausalFemales (Follicular Phase) 82-290 ng/dLPediatricPremature Infants(31-35 Weeks): 235 ng/dL or LessTerm Infants, 3 days old: 170 ng/dL or LessACTH Stimulation

Baseline 60 Minutes1-12 Months 10-200 ng/dL 79-390 ng/dL1-5 Years 7-210 ng/dL 98-360 ng/dL6-12 Years 14-140 ng/dL 95-320 ng/dLTanner Stages II-IIIMale 11-150 ng/dL 115-280 ng/dLFemales 15-130 ng/dL 90-250 ng/dLTanner Stages IV-VMales 14-120 ng/dL 87-210 ng/dLFemales 17-120 ng/dL 78-240 ng/dL

26

Deoxypyridinoline (DPD),Free 2279NIncludes CreatininePreferred Specimen:2 mL urine (1 mL minimum).Reference Range:PremenopausalFemales: 2.1-9.5 nmol/mmol creatinineMales: 2.0-6.6 nmol/mmol creatinineTest results within the premenopausal reference range donot rule out osteoporosis or the need for therapy.Pediatric Reference Ranges for Deoxypyridinoline,Free, Urine

Males Females nmol/mmol Creatinine

5-10 Years 8.0-44.0 6.0-46.011-16 Years 2.0-58.0 2.0-34.016-17 Years 13.0 or less 28.0 or lessCreatinine, Random Urine:Age g/L n0-6 Months 0.02-0.32 577-11 Months 0.02-0.36 231-2 Years 0.02-1.28 573-8 Years 0.02-1.49 1049-12 Years 0.02-1.83 38Adults 0.27-3.00 104

Dexamethasone 140624PPreferred Specimen:2 mL serum (0.6 mL minimum).Reference Range:Baseline: Less than 20 ng/dL1 mg dexamethasone overnight: 180-550 ng/dL

(8:00-10:00 AM)

27

DHEA (Dehydroepiandrosterone),Serum 21964PMethodology:Extraction, RIAPreferred Specimen:1 mL serum(0.3 mL minimum; pediatric absolute minimum 0.1 mL).Reference Range:Males 180-1250 ng/dLFemales 130-980 ng/dLFemales, Pregnancy 135-810 ng/dLPost-ACTH Stimulation 60 MinutesMales and Females 545-1845 ng/dLPediatric Reference Ranges for DHEA, SerumPremature Infants(31-35 Weeks): 3343 ng/dL or LessTerm Infants,1st Week of Life: 761 ng/dL or LessACTH Stimulation

Baseline 60 Minutes<1 Year 26-585 ng/dL 18-1455 ng/dL1-5 Years 9-42 ng/dL 21-98 ng/dL6-12 years 11-155 ng/dL 34-320 ng/dLTanner Stages II-IIIMales 25-300 ng/dL 62-390 ng/dLFemales 69-605 ng/dL 95-885 ng/dLTanner Stages IV-VMales 100-400 ng/dL 195-510 ng/dLFemales 165-690 ng/dL 325-1460 ng/dL

28

DHEA Sulfate 21915PMethodology:Chemiluminescence immunoassayPreferred Specimen:1 mL serum(0.3 mL minimum; pediatric absolute minimum 0.165 mL).Reference Range:Premature Infants (31-35 Weeks) 700 µg/dL or lessTerm Infants, 1st Week of Life 360 µg/dL or lessAge Females Males

(µg/dL) (µg/dL)1- 5 Months 5- 55 41 or less6-11 Months 5- 30 5-201- 5 Years 20 or less 40 or less6- 9 Years 140 or less 145 or less10-11 Years 15-260 15-11512-14 Years 20-535 20-50015-17 Years 35-535 30-555Tanner Stages Females MalesStage (µg/dL) (µg/dL)I 5-125 5-265II 15-150 15-380III 20-535 60-505IV 35-485 65-560V 75-530 165-500Age Females (µg/dL)18-29 Years: 62-61530-39 Years: 52-40040-49 Years: 44-35250-59 Years: 39-183≥60 Years: 11-150Age Males (µg/dL)18-30 Years 125-61931-50 Years: 59-45251-60 Years: 20-41361-83 Years: 10-285

29

Dihydrotestosterone 67751PMethodology:Extraction, column chromatography, RIAPreferred Specimen:4 mL serum(1.1 mL minimum; pediatric absolute minimum 0.5 mL).Reference Range:Males 25-75 ng/dLFemales 5-30 ng/dLPediatric Reference Ranges

Males FemalesCord Blood <2-8 ng/dL <2-5 ng/dL1-6 Months 12-85 ng/dL <5 ng/dLPrepubertal <5 ng/dL <5 ng/dLTanner Stages II-III 3-33 ng/dL 5-19 ng/dLTanner Stages IV-V 22-75 ng/dL 3-30 ng/dL

Estradiol, 24-Hour Urine 3566NIncludes Creatinine.Preferred Specimen:5 mL urine (1 mL minimum).Reference Range:Males:2-10 Years: 0.6 µg/g creatinine or less11-17 Years: 1.5 µg/g creatinine or lessAdults: 1.0-4.0 µg/g creatinineFemales2-10 Years: 0.6 µg/g creatinine or less11-17 Years: 7.2 µg/g creatinine or lessAdults:Follicular Phase: 1.0-13.0 µg/g creatinineMid-Cycle: 4.0-20.0 µg/g creatinineLuteal Phase: 1.0-17.0 µg/g creatinineCreatinine, UrineAGE (years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

30

Estradiol, Free 41772NIncludes total estradiol (Estradiol, serum, ultrasensitive).Methodology:Extraction, equilibrium dialysis, RIAPreferred Specimen:3 mL serum (1.2 mL minimum).Reference Range:Prepubertal boys and girls have free estradiol valuessimilar to those of adult malesFemalesFollicular: 0.60-3.20 pg/mLMidcycle Peak: 0.49-1.09 pg/mLLuteal: 0.30-4.10 pg/mLPostmenopausal: 0.23 pg/mL or lessMales (Adult): 0.30-0.90 pg/mLEstradiol, % Free:FemalesFollicular: 1.49-2.04%Midcycle Peak: 1.59-2.13%Luteal: 1.52- 2.03%Postmenopausal: 1.50-2.85%Males (Adult): 1.66-2.11%Estradiol:FemalesEarly Follicular: 20-150 pg/mLLate Follicular: 40-350 pg/mLMidcycle Peak: 150-750 pg/mLLuteal: 30-450 pg/mLPostmenopausal: 20 pg/mL or lessMales (Adult): 10- 50 pg/mLFor total serum estradiol reference ranges, seeEstradiol, Ultrasensitive (Test Code 30289N)

31

Estradiol, Ultrasensitive 30289NMethodology:Extraction, chromatography, RIAPreferred Specimen:2.5 mL serum(0.6 mL minimum; pediatric absolute minimum 0.5 mL)Reference Range:Adult males: 10-50 pg/mLAdult females:Early follicular phase: 20 - 150 pg/mLLate follicular phase: 40 - 350 pg/mLMid-cycle peak: 150 - 750 pg/mLLuteal phase: 30 - 450 pg/mLPostmenopausal: 20 pg/mL or lessAge Males Females1-5 years 3-10 pg/mL 5-10 pg/mL6-9 years 3-10 pg/mL 5-60 pg/mL10-11 years 5-10 pg/mL 5-300 pg/mL12-14 years 5-30 pg/mL 25-410 pg/mL15-17 years 5-45 pg/mL 40-410 pg/mLBy Tanner stage:Stage Males FemalesI (age 7 and up) 3-15 pg/mL 5-10 pg/mLII 3-10 pg/mL 5-115 pg/mLIII 5-15 pg/mL 5-180 pg/mLIV 3-40 pg/mL 25-345 pg/mLV 15-45 pg/mL 25-410 pg/mL

32

Estriol, 24-Hour Urine 1818NIncludes Creatinine.Preferred Specimen:5 mL urine (1 mL minimum).Reference Range:Males:2-10 Years: 2.3 µg/g creatinine or less11-17 Years: 5.7 µg/g creatinine or lessAdults: 2.0-19.0 µg/g creatinineFemales2-10 Years: 2.3 µg/g creatinine or less11-17 Years: 33.0 µg/g creatinine or lessAdults:Follicular Phase: 3.0-48.0 µg/g creatinineMid-Cycle: 20.0-130.0 µg/g creatinineLuteal Phase: 9.0-60.0 µg/g creatinineCreatinine, Urine:Age(years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

Estriol, Serum 22517PPreferred Specimen:1 mL serum (0.3 mL minimum).Reference Range:Adult Males: 0.2 ng/mL or lessAdult Females (nonpregnant): 0.1 ng/mL or lessPregnancy:6.0-16.5 weeks gestation: 0.1-1.60 ng/mL17.0-24.0 weeks gestation: 1.5 -5.8 ng/mL25.0-32.5 weeks gestation: 2.7 -9.0 ng/mL33.0-40.0 weeks gestation: 7.2-28.0 ng/mL

33

Estrogen, Total,24-Hour Urine 3533NIncludes Creatinine.Preferred Specimen:5 mL urine (1 mL minimum).Reference Range:Males: 4- 23 µg/g creatinineFemalesFollicular Phase: 7- 65 µg/g creatinineMid-Cycle: 32-104 µg/g creatinineLuteal Phase: 8-135 µg/g creatinineCreatinine, Urine:Age (years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

Estrone, 24-Hour Urine 3541NIncludes Creatinine.Preferred Specimen:5 mL urine (1 mL minimum).Reference Range:Estrone (E1), 24-Hour Urine:Males:2-10 Years: 1.2 µg/g creatinine or less11-17 Years: 3.1 µg/g creatinine or lessAdults: 2.0-8.0 µg/g creatinineFemales2-10 Years: 1.2 µg/g creatinine or less11-17 Years: 16.0 µg/g creatinine or lessAdults:Follicular Phase: 2.0-39.0 µg/g creatinineMid-Cycle: 11.0-46.0 µg/g creatinineLuteal Phase: 3.0-52.0 µg/g creatinineCreatinine, 24-Hour Urine:AGE (years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

34

Estrone, Serum 22582PPreferred Specimen:4 mL serum (1.1 mL minimum).Reference Range:Adult FemalesEarly Follicular Phase: 15-150 pg/mLLate Follicular Phase: 100-250 pg/mLLuteal Phase: 15-200 pg/mLPostmenopausal: 15- 55 pg/mLAdult Male: 15- 65 pg/mLPediatric Ranges:Cord Blood: 9000-34000 pg/mL1-4 days: 15-300 pg/mLPrepubertal Children: 5-15 pg/mLPubertalTanner StageII Males: 10- 22 pg/mL

Females: 10- 33 pg/mLIII Males: 17- 25 pg/mL

Females: 15- 43 pg/mLIV Males: 21- 35 pg/mL

Females: 16- 77 pg/mLV Males: 18- 45 pg/mL

Females: 29- 77 pg/mL

Fructosamine 22947PPreferred Specimen:1 mL serum(0.5 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males and Females: 190-270 µmol/LPediatric Reference Range:Children over 5 years of age appear to have valuessimilar to adults.

35

FSH (Follicle Stimulating Hormone),Pediatrics 1024NThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Methodology:Immunoradiometric assay (IRMA)Preferred Specimen:1 mL serum (0.25 mL minimum).Reference Range:Females:Follicular phase: 1.37- 9.90 IU/LMid-Cycle peak: 6.17- 17.20 IU/LLuteal phase: 1.09- 9.20 IU/LPost-Menopausal: 14.90-124.30 IU/LMales:19-70 yrs of age 1.48- 14.26 IU/L

CHILDREN Chronological AgeAge Observed Range (IU/L)

Males Females2 Weeks 1.22-5.19 2.09-30.451-18 mos 0.19-2.97 1.14-14.3519 mos-7 yr 0.25-1.92 0.70-3.398-9 yrs 0.30-1.67 0.28-5.6410-11 yrs 0.20-5.79 0.68-7.2612-14 yrs 0.23-10.37 1.02-9.2415-18 yrs 0.81-8.18 0.33-10.54

Tanner StageStage Observed Range (IU/L)

Males FemalesI 0.22-1.92 0.50-2.41II 0.72-4.60 1.73-4.68III 1.24-10.37 2.53-7.04IV 1.70-10.35 1.26-7.37V 1.54-7.00 1.02-9.24

36

GAD/ICA 512/Insulin AntibodyHighly Sensitive 10584NGlutamic Acid Decarboxylase-65 Autoantibodies; IsletCell Antigen 512 Autoantibodies; Insulin Antibodies,Highly SensitiveFor individual assays see Glutamic Acid Decarboxylase-65 Aantibodies, Islet Cell Antigen 512 autoantibodies,and Insulin Antibodies, Highly Sensitive.GAD-65 Antibody: This test was performed using a kit thathas not been cleared or approved by the FDA. Theanalytical performance characteristics of this test havebeen determined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established meansICA 512 Antibody and Insulin Antibodies, HighlySensitive: This test was developed and its performancecharacteristics determined by Quest DiagnosticsNichols Institute. It has not been cleared or approved bythe U.S. Food and Drug Administration. The FDA hasdetermined that such clearance or approval is notnecessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:2 mL serum(0.4 mL minimum; pediatric absolute minimum 0.25 mL).Reference Range:See individual assays.

37

Gastrin 23333PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been cleared orapproved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:2 mL serum (0.5 mL minimum).Reference Range:Adults: < 42 pg/mLObserved ranges Mean

(pg/mL) (pg/mL)Newborns (1-12 days) 130 69 - 190Infants (1.5-22 months) 101 55 - 186Prepubertal and pubertal childrenFasting 3-4 hours 59 168 or lessFasting 5-6 hours 42 117 or lessFasting 8 hours or more 23 125 or less

Glucagon 23382PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:3 mL plasma (1.1 mL minimum).Reference Range:Males and Females 20-100 pg/mLPediatric Reference RangesCord Blood 215 pg/mL or LessDay 1 240 pg/mL or LessDay 2 400 pg/mL or LessDay 3 420 pg/mL or Less4-14 Days 148 pg/mL or Less

38

Glutamic Acid Decarboxylase-65Autoantibodies 139261PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.05 mL).Reference Range:1.0 or less U/mL

Growth Hormone (hGH) 29637PPreferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:Adults: 10.0 or less ng/mLChildren: 13.0 or less ng/mLBecause of diurnal variability random growth hormonevalues are not reliable for diagnosis of growth hormonedeficiency, acromegaly (adults) or gigantism (pediatrics).Growth Hormone, Serum(following 75 g Oral Glucose):Adults: Less than 1 ng/mL

Growth Hormone Antibody 42218NThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been cleared orapproved by the U.S. Food and Drug Administration. TheFDA has determined that such clearance or approval isnot necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:0.5 mL serum (0.2 mL minimum).Reference Range:Children and Adults: Negative

39

Growth Hormone BindingProtein 110155PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum (0.1 mL minimum)Reference Range:40-425 pmol/LThis assay has been recently upgraded. A larger pediatricreference range study is in progress (April 2004).

Growth Hormone ReleasingHormone 141770PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:4 mL plasma(1.1 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males and Females 49 pg/mL or LessPediatric Reference Ranges:4-14 Years 6.8-19.0 pg/mL

hCG, Total, Quantitative(Pregnancy) 21113PPreferred Specimen:1 mL serum (0.4 mL minimum).Reference Range:Children and Adults: < 5 mIU/mL

40

hCG, Total, Quantitative(Tumor) 5140NNo hCG assay has been approved by the FDA as a tumormarker.Preferred Specimen:1 mL serum (0.4 mL minimum).Reference Range:< 5 mIU/mLThe Bayer Chemiluminescence assay was used todetermine this result. The use of this assay to monitor orto diagnose patients with cancer has not been approvedby the FDA or the manufacturer of the assay. hCG valuesobtained with different assay methods or kits cannot beused interchangeably.

Hemoglobin A1c 45484PPreferred Specimen:2 mL whole blood(0.3 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:Non-Diabetic: 4.5 - 5.9 %American Diabetes Association (ADA) goal of therapyin diabetes mellitus: < 7%ADA-recommended threshold for re-evaluation oftreatment if results are consistently: >8 %

5-HIAA (5-Hydroxyindoleacetic Acid),24-Hour Urine 9936NPreferred Specimen:10 mL urine (5 mL minimum).Reference Range:2-10 years: 8.0 or less mg/24 hr>10 years: 6.0 or less mg/24 hr

41

Histamine, 24-Hour Urine 6825NIncludes CreatinineThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:4 mL urine (2 mL minimum).Reference Range:Males: 5.0-29.5 µg/g creatFemales: 4.6-42.4 µg/g creatCreatinine, 24-Hour Urine:Age (years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

Histamine, Plasma 24166PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL plasma (0.2 mL minimum).Methodology:Radioimmunoassay

42

Histamine, Random Urine 86447NIncludes CreatinineThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL urine (0.3 mL minimum).Reference Range:Adults: 65.4 or less µg/g creatCreatinine, Random Urine:Age g/L n0-6 Months 0.02-0.32 577-11 Months 0.02-0.36 231-2 Years 0.02-1.28 573-8 Years 0.02-1.49 1049-12 Years 0.02-1.83 38Adults 0.27-3.00 104

Histamine, Whole Blood 24158PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1.6 mL whole blood (0.6 mL minimum).Reference Range:9-141 ng/mL

43

Homovanillic Acid,24-Hour Urine 1248NPreferred Specimen:10 mL urine (5 mL minimum).Reference Range:Age (years) mg/24-hours n3-8 0.5-6.7 769-12 1.1-6.8 4413-17 1.4-7.2 4Adults 1.6-7.5

Homovanillic Acid,Random Urine 84855NIncludes Creatinine.Preferred Specimen:10 mL urine (5 mL minimum).Reference Range:Age mg/g creatinine nBirth-6 Months 9.1-36 407-11 Months 11.2-33 201-2 Years 8.5-38 423-8 Years 2.1-23 959-12 Years 1.1-12 32Adults 1.4-5.3 91Creatinine, Random Urine:Age g/L n0-6 Months 0.02-0.32 577-11 Months 0.02-0.36 231-2 Years 0.02-1.28 573-8 Years 0.02-1.49 1049-12 Years 0.02-1.83 38Adults 0.27-3.00 104

44

18-Hydroxycorticosterone(18-OH-B) 16741PPreferred Specimen:3 mL serum (1.1 mL minimum).Reference Range:

Upright SupineAdult (8-10 AM) 5-80 ng/dL 4-37 ng/dLPremature Infants(31-35 Weeks) 380 ng/dL or LessTerm Infants, 3 days old 942 ng/dL or lessACTH Stimulation

Baseline 60 Minutes1-12 Months 5-310 ng/dL 67-470 ng/dL1-5 Year 7-155 ng/dL 49-370 ng/dL6-12 Years 10-74 ng/dL 79-360 ng/dLTanner Stages II-IIIMales 5-73 ng/dL 91-1475 ng/dLFemales 11-82 ng/dL 69-195 ng/dLTanner Stages IV-VMales 14-62 ng/dL 73-205 ng/dLFemales 11-68 ng/dL 82-320 ng/dL

18-hydroxycortisol, Free,24-Hour Urine 11178XMethodology:Liquid chromatography/tandem mass spectrometryPreferred Specimen:10 mL urine (2.1 mL minimum).Reference Range:Males: 43-295 µg/24 hrFemales: 51-515 µg/24 hr

45

18-Hydroxydeoxycorticosterone(18-OH-DOC) 112060PMethodology:Extraction, Chromatography, RIAPreferred Specimen:5 mL serum (1.1 mL minimum).Reference Range:

AM PMMales and Females 3-13 ng/dL 3-8 ng/dLPediatricCord Blood 40 ng/dL or Less1 Day 4-21 ng/dL or Less6 Days 34 ng/dL or Less

21-Hydroxylase Antibody 177816PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.05 mL).Reference Range:< 1.0 U/mL

46

17-Hydroxypregnenolone 67652PMethodology:Extraction, chromatography, RIAPreferred Specimen:2 mL serum (0.4 mL minimum).Reference Range:Males and Females 20-450 ng/dLPost-ACTH Stimulation 60 MinutesMales & PremenopausalFemales (Follicular Phase) 290-910 ng/dLPediatric Reference Ranges for

17 Hydroxypregnenolone, SerumPremature Infants(31-35 weeks) 2409 ng/dL or lessTerm Infants, 3 days old 830 ng/dL or lessACTH Stimulation

Baseline 60 Minutes1-12 Months 14-830 ng/dL 395-3290 ng/dL1-5 Years 10-100 ng/dL 45-740 ng/dL6-12 Years 11-190 ng/dL 70-660 ng/dLTanner Stages II-IIIMales 20-360 ng/dL 88-675 ng/dLFemales 58-450 ng/dL 250-800 ng/dLTanner Stages IV-VMales 32-300 ng/dL 220-860 ng/dLFemales 53-540 ng/dL 500-1600 ng/dL

47

17-Hydroxyprogesterone 16691PMethodology:Extraction, RIAPreferred Specimen:1 mL serum(0.1 mL minimum; pediatric absolute minimum 0.05 mL).Reference Range:Males 50-250 ng/dLFemaleFollicular Phase 20-100 ng/dLMidcycle Peak 100-250 ng/dLLuteal Phase 100-500 ng/dLPostmenopausal 70 ng/dL or lessPost-ACTH Stimulation 60 MinutesMales and PremenopausalFemales (Follicular Phase) 42-250 ng/dLPremature Infants(31-35 Weeks) 360 ng/dL or lessTerm Infants,Birth-5 Days Old 420 ng/dL or lessACTH Stimulation

Baseline 60 Minutes1-12 Months 11-170 ng/dL 85-465 ng/dL1-5 Years 4-115 ng/dL 50-350 ng/dL6-12 Years 7-69 ng/dL 75-220 ng/dLTanner Stages II-IIIMales 12-130 ng/dL 69-310 ng/dLFemales 18-220 ng/dL 80-420 ng/dLTanner Stages IV-VMales 51-190 ng/dL 105-230 ng/dLFemales 36-200 ng/dL 80-225 ng/dL

48

IGF-I (Somatomedin-C) 24844PMethod:ChemiluminescencePreferred Specimen:1 mL serum (R), frozenMinimum 0.4 mLPediatric minimum: 0.1 mLReference Range:IGF-I Reference Ranges (ng/mL):AGE MALE FEMALE2 Mo - 5 Years 17-248 17- 2486 - 8 Years 88-474 88- 4749 - 11 Years 110-565 117- 77112 -15 Years 202-957 261-109616 - 24 Years 182-780 182- 78025 - 39 Years 114-492 114- 49240 - 54 Years 90-360 90- 360>55 Years 71-290 71- 290Tanner StageStage Males n Females n

(ng/mL) (ng/mL)I 109-485 95 128-470 122II 174-512 64 186-695 49III 230-818 31 292-883 50IV 396-776 20 394-920 41V 402-839 47 308-1138 107

IGF Binding Protein-1(IGFBP-1) 127225PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Method:RadioimmunoassayPreferred Specimen:1 mL serum (R), frozenMinimum 0.2 mLReference Range:13.0-73.0 ng/mL

49

IGF Binding Protein-2(IGFBP-2) 127233PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Method:RadioimmunoassayPreferred Specimen:1 mL serum (R), frozenMinimum 0.2 mLReference range:1 - 9 Years: 69-480 ng/mL10 - 17 Years: 50-326 ng/mL18 - 49 Years: 55-240 ng/mL >49 Years: 28-444 ng/mL

IGF Binding Protein-3(IGFBP-3) 24836PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Method:RadioimmunoassayPreferred Specimen:1 mL serum (R), frozenMinimum 0.2 mLPediatric minimum: 0.1 mLReference Range:2 - 23 Months: 0.7-2.3 mg/L2 - 7 Years: 0.9-4.1 mg/L8 - 11 Years: 1.5-4.3 mg/L12 - 18 Years: 2.2-4.2 mg/L19 - 55 Years: 2.0-4.0 mg/L56 - 82 Years: 0.9-3.7 mg/L

50

Inhibin A 24786PPreferred Specimen:2 mL serum (0.5 mL minimum).Reference Range:FemalesPremenopausal: Less than 98 pg/mLPostmenopausal: Less than 10 pg/mLMales Less than 21 pg/mLThis test was performed using the DSL ACTIVE® Inhibin-A ELISA method that has been approved by the FDAstrictly for in vitro use as an aid in the diagnosis andmonitoring of various hormonal reproductive disorders.The inhibin A test should not be used as a diagnosticprocedure for granulosa cell tumors without confirmationof the diagnosis by another established product orprocedure. Values obtained with different assay methodsor kits cannot be used interchangeably.

Inhibin-B, ELISA 34445XThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Preferred Specimen:1 mL frozen serum (0.5 mL minimum).Pre-menopausal females < 255 pg/mLPost-menopausal females < 30 pg/mLMales < 305 pg/mL

Insulin 15701PPreferred Specimen:1 mL serum(0.5 mL minimum; pediatric absolute minimum 0.3 mL).Reference Range:< 17 uIU/mLInsulin levels vary widely in specimens taken from non-fasting individuals.This assay does not show significant cross-reactivitywith proinsulin.

51

Insulin Antibodies,Highly Sensitive 52324PFor detection of insulin autoantibody in patients notreceiving insulin therapy.This test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:1 mL serum (0.3 mL minimum).Reference Range:Children and Adults: 1.1 or less %

Insulin Antibodywith Reflex to Titer 10275NIf Insulin Antibody Screen is positive, Insulin AntibodyTiter is performed at an additional charge. (CPT: 86337)Test is for use in patients receiving insulin therapy. Thistest was developed and its performance characteristicshave been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.02 mL).Reference Range:Children and Adults: Negative

52

Insulin, Free (Bioactive) 69013PThe free (bioactive) insulin test is recommended forpatients who have detectable levels of insulin antibodies.This test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:3 mL serum (0.6 mL minimum).Reference Range:4.0-20.0 (Adults) uU/mLInsulin levels vary widely in specimens taken from non-fasting individuals.

Insulin, Total(Free and Antibody Bound) 36954PThis test is recommended for patients who havedetectable levels of insulin antibodies.This test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:3 mL serum (0.6 mL minimum).Reference Range:20 or less uU/mLIndividuals with circulating Insulin antibodies maydemonstrate variable concentrations depending upon thebinding capacity of the circulating antibodies. Insulinlevels vary widely in specimens taken from non-fastingindividuals.

53

Islet Cell Antigen 512Autoantibodies 86736NThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:1 mL serum(0.5 mL minimum; pediatric absolute minimum 0.05 mL).Reference Range:<0.8 U/mL

17-Ketosteroids,24-Hour Urine 33753NPreferred Specimen:15 mL urine (5 mL minimum).Reference Range:

Males FemalesAge mg/24 hrs n mg/24 hrs n2-17 years 0.8-8.1 55 0.8-8.1 55Adults 7-20 103 5-15 103

54

17-Ketosteroids,Fractionated, Urine 42929NIncludes Creatinine.Preferred Specimen:5 mL urine (2.6 mL minimum).Reference Range:AndrosteroneAdult males: 320-5400 µg/24 hrAdult females: 240-2300 µg/24 hrAndrosteroneAdult males: 430-2500 µg/g CreatAdult females: 150-2100 µg/g Creat<1 year 3-255 µg/g Creat1-4.9 years 4-378 µg/g Creat5-9.9 years 16-830 µg/g Creat10-13.9 years 102-1510 µg/g Creat14-17.9 years <2750 µg/g CreatEtiocholanoloneAdult males: 430-3300 µg/24 hrAdult females: 245-2300 µg/24 hrEtiocholanolone adults: 280-2100 µg/g Creat<1 year 6-29 µg/g Creat1-4.9 years 2-261 µg/g Creat5-9.9 years 18-465 µg/g Creat10-13.9 years 98-1746 µg/g Creat14-17.9 years 104-2006 µg/g CreatDHEA adults: 21-2170 µg/24 hrDHEAAdult males: 24-1640 µg/g CreatAdult females: 13-730 µg/g Creat<1 year 100 µg/g Creat or less1-4.9 years 100 µg/g Creat or less5-9.9 years 100 µg/g Creat or less10-13.9 years 5-316 µg/g Creat14-17.9 years 15-732 µg/g Creat11-Oxo-AndrosteroneAdult males: 15-111 µg/24 hrAdult females: 8-87 µg/24 hr11-Oxo-Androsterone adults: 13-84 µg/g Creat<6 months 13-578 µg/g Creat<1 year 1-200 µg/g Creat1-4.9 years 3-69 µg/g Creat5-9.9 years 6-118 µg/g Creat10-13.9 years 4-104 µg/g Creat14-17.9 years 8-106 µg/g Creat

55

11-Oxo-Etiocholanolone adults: 78-1165 µg/24 hr11-Oxo-Etiocholanolone adults: 68-870 µg/g Creat<1 year 6-29 µg/g Creat1-4.9 years 2-261 µg/g Creat5-9.9 years 18-465 µg/g Creat10-13.9 years 98-1746 µg/g Creat14-17.9 years 104-2006 µg/g Creat11β-HydroxyandrosteroneAdult males: 130-900 µg/24 hrAdult females: 195-1500 µg/24 hr11β-Hydroxyandrosterone adults: 180-850 µg/g Creat<1 year 143-1180 µg/g Creat1-4.9 years 23-673 µg/g Creat5-9.9 years 44-677 µg/g Creat10-13.9 years 100-802 µg/g Creat14-17.9 years 68-1152 µg/g Creat11b-Hydroxyetiocholanolone adults: 14-680 µg/24 hr11b-Hydroxyetiocholanolone adults: 8-580 µg/g Creat<1 year 105 µg/g Creat or less1-4.9 years 403 µg/g Creat or less5-9.9 years 7-716 µg/g Creat10-13.9 years 10-363 µg/g Creat14-17.9 years 740 µg/g Creat or lessPregnanetriolAdult males: 71-1000 µg/24 hrAdult females: 47-790 µg/24 hrPregnanetriol<1 year 49-345 µg/g Creat (random)1-4.9 16-233 µg/g Creat (random)5-9.9 27-214 µg/g Creat10-13.9 19-563 µg/g Creat14-17.9 15-817 µg/g CreatAdults 53-530 µg/g CreatCreatinine, Urine:Age (Years) g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

56

Leptin 84657NThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:Adult Lean Subjects with BMI range of 18-25:Adult Males: 1.2-9.5 ng/mLAdult Females: 4.1-25.0 ng/mLBMI = Body MassIndex = Body weight in kilograms/(Height in Meters)2

Pediatric reference ranges:Male Female

Prepubertal 1.6-10.8 ng/mL 1.7-10.6 ng/mLTanner Stages II-III 2.1-11.6 ng/mL 2.6-11.5 ng/mLTanner Stages IV-V 3.4-10.2 ng/mL 3.4-13.0 ng/mL

57

LH, (Luteinizing Hormone)Pediatrics 1032NThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Methodology:Immunochemiluminometric assay (ICMA)Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:Females:Follicular phase: 1.68-15.00 IU/LMid-Cycle peak: 21.94-56.60 IU/LLuteal phase: 0.61-16.30 IU/LPost-Menopausal: 9.00-52.30 IU/LMales:19-70 years of age 0.95-5.60 IU/LChildrenAge Chronological Stage Tanner Stage

Observed Range Observed Range(IU/L) (IU/L)

MalesCord Blood 0.04-2.602 weeks 4.85-10.021-18 months 0.04-3.01 I 0.02-0.4219 mos-7 years 0.02-1.03 II 0.26-4.848-9 years 0.01-0.78 III 0.64-3.7410-11 years 0.03-4.44 IV 0.55-7.1512-14 years 0.25-4.84 V 1.54-7.0015-18 years 0.69-7.15FemalesCord Blood 0.04-2.602 weeks 0.29-7.911-18 months 0.02-1.77 I 0.01-0.2119 mos-7 years 0.03-0.55 II 0.27-4.128-9 years 0.02-0.24 III 0.17-4.1210-11 years 0.02-4.12 IV 0.72-15.0112-14 years 0.28-29.38 V 0.30-29.3815-18 years 0.11-29.38

58

Metanephrines, Fractionated,LC/MS/MS, 24-Hour Urine 14962XIncludes metanephrine, normetanephrine, totalmetanephrines and creatinine.This test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Preferred Specimen:5 mL room temperature urine (1 mL minimum).Reference Range:Pediatric ranges:Metanephrines, Total, Fractionated,24-hour urine ug/24 hours ug/g creat3 months-4.9 years 79-345 246-8275-9.9 years 49-408 205-77710-13.9 years 110-714 100-62814-17.9 years 107-741 113-483Metanephrine, 24-hour Urine3 months-4.9 years 25-117 75-1885-9.9 years 49-408 58-27110-13.9 years 51-275 34-24914-17.9 years 40-189 28-214Normetanephrine, 24-hour urine3 months-4.9 years 54-249 171-6015-9.9 years 31-398 123-57610-13.9 years 67-503 67-44214-17.9 years 69-531 63-328

59

Microalbumin,24-Hour Urine 4010NThis highly sensitive Albumin assay is used to screenearly renal disease in diabetic patients.Preferred Specimen:2 mL urine (0.5 mL minimum).Reference Range:Children and adults: 30 or less mg/24-hoursThe ADA [Diabetes Care (1997) 20:S24-S27] hasdefined abnormalities in albumin excretion as follows:Category Result (mg/24 hr)Normal <30Microalbuminuria 30-300Clinical albuminuria >300The ADA recommends that at least two of threespecimens collected within a 3-6 month period beabnormal before considering a patient to be within adiagnostic category.

Microalbumin,Random Urine 37924XThis highly sensitive Albumin assay is used to screenearly renal disease in diabetic patients.Preferred Specimen:2 mL urine (0.5 mL minimum).Reference Range:Children and adults: < 30 mg/g creatThe ADA (Diabetes Care (1997) 20:S24-S27) has definedabnormalities in albumin excretion as follows:Category Result (mg/g creatinine)Normal <30Microalbuminuria 30-300Clinical albuminuria >300The ADA recommends that at least two of threespecimens collected within a 3-6 month period beabnormal before considering a patient to be within adiagnostic category.

60

Neuron Specific Enolase(NSE) 22251PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Males and Females Less than 8.6 µg/LPediatric:Cord Blood 4.8-19.5 µg/L12-17 Years 12.0 µg/L or LessNSE is not to be used as a diagnostic procedure withoutconfirmation of the diagnosis by another establishedproduct or procedure. Values obtained with differentassay methods or kits cannot be used interchangeably.This test was performed using the Can Ag, EIA method.

Osmolality, Serum 26922PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:282-303 mOsm/kg

Osmolality,Random Urine 26955PPreferred Specimen:1 mL urine (0.2 mL minimum).Reference Range:200-1192 mOsm/kg

61

Osteocalcin, Human(Bone Gla Protein, BGP) 26971PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Adult males: 11.3-35.4 ng/mLAdult females: 7.2-27.9 ng/mL

Pancreatic Polypeptide 27219PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:2 mL plasma (0.6 mL minimum).Reference Range:Males and Females:20-29 Years 26-158 pg/mL30-39 Years 55-284 pg/mL40-49 Years 64-243 pg/mL>50 Years 51-326 pg/mLPediatricCord Blood:Term Infants 163 pg/mL or LessPreterm Infants 180 pg/mL or LessTerm Infants-6 Days 276 pg/mL or Less1 Month-2 Years 644 pg/mL or Less3-7 Years 685 pg/mL or Less>7 Years 80-270 pg/mL

62

Parietal Cell Antibody Screenw/Reflex to Titer 42093NParietal Cell Antibody Screen; Parietal Cell AntibodyTiter at an additional charge. (CPT: 86256)Preferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Screen: NegativeTiter: <1:20

Plasma Renin Activity 10537NThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance or approvalis not necessary. Performance characteristics refer to theanalytical performance of the test.Preferred Specimen:3 mL plasma(0.4 mL minimum; pediatric absolute minimum 0.3 mL).Reference Range:Adults (a.m. and p.m.)Supine 0.3-3.0 ng/mL/hrUpright 0.4-8.8 ng/mL/hrRenovascular Hypertension >10 ng/mL/hrPediatricPremature Infants1st Week of Life 34.0 ng/mL/hr or Less2-4 Weeks 147.9 ng/mL/hr or LessFull Term Neonates 26.0 ng/mL/hr or Less

Supine Upright(ng/mL/hr) (ng/mL/hr)

3-12 Months 15.0 or Less1-3 Years 10.0 or Less4-6 Years 7.5 or Less 15.0 or less7-9 Years 5.9 or Less 17.0 or less10-12 Years 5.3 or Less 16.0 or less13-15 Years 4.4 or Less 16.0 or less

63

Prealbumin 67934PPreferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:0-5 Days: 6-21 mg/dL1-5 Years: 14-30 mg/dL6-9 Years: 15-33 mg/dL10-13 Years: 20-36 mg/dL14-17 Years: 22-45 mg/dLAdults Males: 21-43 mg/dLAdult Females: 17-34 mg/dL

Pregnanetriol, Urine 7625NIncludes Creatinine.Preferred Specimen:5 mL urine (2.1 mL minimum).Reference Range:Males: 71-1000 µg/24-hoursFemales: 47-790 µg/24-hoursPregnanetriol, UrineAge µg/g Creatinine<1 year 49-345 (random)1-4.9 16-233 (random)5-9.9 27-21410-13.9 19-56314-17.9 15-817Creatinine, UrineAge g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

64

Pregnenolone 28373PMethodology:Extraction, column chromatography, RIAPreferred Specimen:4 mL serum(1.1 mL minimum; pediatric absolute minimum 1.0 mL).Reference Range:Males 10-200 ng/dLFemales 10-230 ng/dLPediatric ACTH Stimulation

Baseline 60 Minutes<1 Year 10-140 ng/dL 49-360 ng/dL1-5 Years 10-48 ng/dL 34-135 ng/dL6-12 Years 15-45 ng/dL 39-105 ng/dLTanner Stages II-IIIMales 10-45 ng/dL 58-110 ng/dLFemales 15-84 ng/dL 33-140 ng/dLTanner Stages IV-VMales 11-50 ng/dL 37-150 ng/dLFemales 20-77 ng/dL 91-220 ng/dL

Progesterone (Pediatric),Serum 14866XMethodology:Extraction, RIAPreferred Specimen:1 mL serum(minimum volume 0.5 mL; pediatric absolute minimum0.1 mL).Reference Range:Pediatric ACTH Stimulation

Baseline 60 Minutes<1 Year 5-80 ng/dL 74-200 ng/dL1-5 Years 8-64 ng/dl 51-230 ng/dL6-12 Years 5-93 ng/dL 38-200 ng/dLTanner Stages II-IIIMales 64-115 ng/dL 61-185 ng/dLFemales 6-680 ng/dL 32-575 ng/dLTanner Stages IV-VMales 17-145 ng/dL 35-225 ng/dLFemales 16-1290 ng/dL 45-1080 ng/dL

65

Proinsulin 28407PThis test was developed and its performancecharacteristics have been determined by QuestDiagnostics Nichols Institute. It has not been clearedor approved by the U.S. Food and Drug Administration.The FDA has determined that such clearance orapproval is not necessary. Performance characteristicsrefer to the analytical performance of the test.Preferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:Males: <19.1 pmol/LFemales: <8.8 pmol/L

Prolactin 28423PPreferred Specimen:1 mL serum(0.5 mL minimum; pediatric absolute minimum 0.25 mL).Reference Range:Prolactin, SerumMales: 3.0-14.7 ng/mLFemales: 3.8-23.2 ng/mLTanner StageMales (ng/ml)I 10 or less 14II-III 6.1 or less 15IV-V 2.8-11.0 25FemalesI 3.6-12.0 8II-III 2.6-18.0 20IV-V 3.2-20.0 19

PTH Antibody 139287PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Negative

66

PTH, BioIntact (Amino Acids 1-84)and Calcium 10152NPreferred Specimen:2 mL plasma(0.9 mL minimum; pediatric absolute minimum 0.35 mL).Reference Range:BioIntact PTH (1-84) 6-40 pg/mLCalcium, Serum 8.8-10.1 mg/dL

PTH, Intact and Calcium 1222NThe Intact PTH is the recommended initial assay for thedifferential diagnosis of calcium-related abnormalities.Preferred Specimen:2 mL Heparin plasma(1 mL minimum; pediatric absolute minimum 0.35 mL).Reference Range:PTH, Intact: 10-65 pg/mLTo convert pg/mL to pmol/L multiply the result by 0.106.Calcium, Serum: 8.8-10.1 mg/dL

PTH-Related Protein(PTH-rP) 27292PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not beused for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:3 mL plasma (2 mL minimum).Reference Range:1.3 or less pmol/L

67

Pyridinium Collagen Cross-Links,24-Hour Urine 60863NIncludes Creatinine.Preferred Specimen:5 mL urine (1 mL minimum).Reference Range:Pyridinoline nmol/mmol of CreatinineMales 20.0-60.8Females (Premenopausal) 22.1-88.9DeoxypyridinolineMales 3.7-18.7Females (Premenopausal) 4.4-21.1Pediatric Pyridinoline2-10 Years 158.4-441.911-14 Years 106.9-397.615-17 Years 42.0-200.5Deoxypyridinoline2-10 Years 31.1-111.711-14 Years 16.6-100.815-17 Years 58.7 or LessResults are primarily used for monitoring response totherapy. A value within the premenopausal reference rangedoes not rule out osteoporosis nor the need for therapy.Creatinine, UrineAge g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

68

Pyridinium Collagen Cross-Links,2-Hour Urine 7716NIncludes Creatinine.Preferred Specimen:5 mL urine (0.5 mL minimum).Reference Range:Pyridinoline nmol/mmol of CreatinineMales21-56 Years 22.7-65.2FemalesPremenopausal21-50 Years 25.4-82.8DeoxypyridinolineMales21-56 Years 6.2-25.6FemalesPremenopausal21-50 Years 5.7-23.3PediatricPyridinoline2-10 Years 153.0-400.611-17 Years 16.6-408.4Tanner Stage I 112.4-352.8Tanner Stage II 95.3-470.9Tanner Stage III 67.6-488.8Tanner Stage IV 17.3-447.7Deoxypyridinoline2-10 Years 39.0-120.111-17 Years 3.0-117.0Tanner Stage I 26.8-102.8Tanner Stage II 20.4-139.2Tanner Stage III 14.5-135.3Tanner Stage IV 10.0-136.0Results are primarily used for monitoring response totherapy. A value within the premenopausal reference rangedoes not rule out osteoporosis nor the need for therapy.Creatinine, Random UrineAge g/L n0-6 Months 0.02-0.32 577-11 Months 0.02-0.36 231-2 Years 0.02-1.28 573-8 Years 0.02-1.49 1049-12 Years 0.02-1.83 38Adults 0.27-3.00 104

69

Renin, Direct 122499PPreferred Specimen:2 mL plasma (0.55 mL minimum).Reference Range:Low renin sodium/volumemediated hypertension likely: < 5 µU/mLRenin mediatedhypertension likely: ≥ 5 µU/mLApplies only to patients with established hypertension.Renovascular hypertension possible if renin is >10 µU/mL.Primary aldosteronism possible if renin is < 5 µU/mL.Non-hypertensive individuals:Adults (non-hypertensive) 3.3 - 41 uU/mLPediatrics:Cord Blood 39 - 617 uU/mLTerm Newborns (2-4 days) 11 - 759 uU/mL2 wks - 3 mos 11 - 148 uU/mL4 mos - 1 year 7 - 174 uU/mL1-3 years 21 - 102 uU/mL3-5 years 20 - 123 uU/mL5-18 years 7 - 122 uU/mL

Serotonin, Blood 29397PPreferred Specimen:4 mL whole blood(1 mL minimum; pediatric absolute minimum 0.3 mL).Reference Range:22-180 ng/mL

Serotonin, Serum 29405PPreferred Specimen:2 mL serum (1 mL minimum).Reference Range:Adult: 26 - 165 ng/mL1-12 Years: 81 - 349 ng/mL

70

Sex HormoneBinding Globulin 29421PPreferred Specimen:1 mL serum(0.4 mL minimum; pediatric absolute minimum 0.2 mL).Reference Range:Males 7-50 nmol/LFemales 17-120 nmol/LPediatric Males FemalesPreterm Infants 24-56 nmol/L 14-40 nmol/LTerm Infants 24-54 nmol/L 16-44 nmol/L2-8 Years 29-141 nmol/L 41-137 nmol/L9-14 Years 32-92 nmol/L 15-123 nmol/L

Somatostatin 29611PThis test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Preferred Specimen:4 mL plasma (1.1 mL minimum).Reference Range:Adults: 10-22 pg/mL

T3 (Triiodothyronine)Antibody 53967PPreferred Specimen:1 mL serum (0.1 mL minimum).Reference Range:Negative

71

T3, Free, Non-Dialysis 30510PPreferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:Adults: 230-420 pg/dL< 1 year: not established1-9 years: 337 - 506 pg/dL10-13 years: 335 - 480 pg/dL14-18 years: 287 - 455 pg/dL

T3, Free, Tracer Dialysis 3434NIncludes Total T3, Free T3Preferred Specimen:1 mL serum (0.4 mL minimum).Reference Range:210-440 pg/dLA pediatric reference range study (n=246 to date) is inprogress. Preliminary data suggest the followingreference ranges (+/- 2 SD):1-9 years: 300 - 525 pg/dL10-13 years: 290 - 545 pg/dL14-18 years: 230 - 495 pg/dLPregnancy Reference Ranges forFree T3: 200-380 pg/dL (all trimesters)T3, Total: 60-181 ng/dL

T3, Reverse 30528PThis test was performed using a kit that has not beencleared or approved by the FDA. The analyticalperformance characteristics of this test have beendetermined by Quest Diagnostics Nichols Institute.This test should not be used for diagnosis withoutconfirmation by other medically established means.Preferred Specimen:1 mL serum(0.2 mL minimum; pediatric absolute minimum 0.125).Reference Range:Cord blood: 102-342 ng/dL1 month-20 years: 10-35 ng/dLAdults: 10-24 ng/dL

72

T3, Total (Triiodothyronine) 30536PPreferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:Adults: 60-181 ng/dL< 1 year: not established1-9 years: 127 - 221 ng/dL10-13 years: 123-211 ng/dL14-18 years: 97 - 186 ng/dL

T4 (Thyroxine) Antibody 95802PPreferred Specimen:1 mL serum (0.1 minimum).Reference Range:Negative

T4, Free, Direct Dialysis 68924PDirect dialysis is the preferred method for determiningfree T4. Free T4 is measured in undiluted serum byradioimmunoassay of the dialyzable T4.Preferred Specimen:2 mL serum(0.2 mL minimum; pediatric absolute minimum 0.15 mL).Reference Range:Prematures, 25-30 Weeks,Birth-7 Days 0.5-3.3 ng/dLPrematures, 31-36 Weeks,Birth-7 Days 1.3-4.7 ng/dLCord Blood, >37 Weeks 1.2-2.2 ng/dLBirth-4 Days 2.2-5.3 ng/dL2 Weeks-20 Years 0.8-2.0 ng/dL21-87 Years 0.8-2.7 ng/dLPregnancy:First Trimester 0.7-2.0 ng/dLSecond Trimester 0.5-1.6 ng/dLThird Trimester 0.5-1.6 ng/dL

73

T4, Free, Non-Dialysis 30247PPreferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:Adults: 0.8-1.8 ng/dL< 1 year: not established1-9 years: 0.9 - 1.6 ng/dL10-18 years: 0.9 - 1.4 ng/dL

T4, Total (Thyroxine) 30262PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Age µg/dLPrematures, 28-36 Weeks,1st Week of Life 4.0-17.4Cord Blood, >37 Weeks 5.9-15.00-4 Days 14.0-28.42-20 Weeks 8.1-15.721 Weeks - 20 Years 5.6-14.9Adult 5.6-13.7Pregnancy:1st Trimester 8.0-17.12nd Trimester 8.0-17.83rd Trimester 8.0-20.1

Tartrate Resistant AcidPhosphatase 84665NPreferred Specimen:1 mL serum (0.3 mL minimum).Reference Range:2.0-4.2 U/L

74

TBG(Thyroxine Binding Globulin) 30213PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Age Males Females

(mg/dL) (mg/dL)Cord Blood,>37 Weeks 2.1-3.7 2.1-3.71- 5 Days 2.2-4.2 2.2-4.21-11 Months 1.6-3.6 1.7-3.71- 9 Years 1.2-2.8 1.5-2.710-19 Years 1.4-2.6 1.4-3.020-90 Years 1.7-3.6 1.7-3.6

TBII (Thyrotropin-Binding InhibitoryImmunoglobulin) 30171PPreferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:Less than 10% inhibitionGraves Disease patients show an inhibition of10-100%Note: The reported value is the percent inhibition of125I-TSH binding to the thyroid TSH receptor.

Testosterone, Free and Total 4960NIncludes Total Testosterone.This test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Methodology:Extraction, chromatography, equilibrium dialysis, RIAPreferred Specimen:3 mL serum (0.5 mL minimum).

75

Reference Range:Testosterone, Total Total (ng/dL)Males 260-1000FemalesPremenopausal 15-70Postmenopausal 5-51 (Without Estrogen Therapy)PediatricMales Total (ng/dL)Cord Blood 17-611-10 Days 187 or Less1-3 Months 72-3443-5 Months 201 or Less5-7 Months 59 or Less7-12 Months 16 or Less1-5 Years 12 or Less6-9 Years 3-3010-11 Years 5-5012-14 Years 10-57215-17 Years 220-800Tanner Stage I 2-23Tanner Stage II 5-70Tanner Stage III 15-280Tanner Stage IV 105-545Tanner Stage V 265-800Females Total (ng/dL)Cord Blood 16-441-10 Days 24 or Less1-3 Months 17 or Less3-5 Months 12 or Less5-7 Months 13 or Less7-12 Months 11 or LessFemales Total (ng/dL)1-5 Years 12 or Less6-9 Years 2-2010-11 Years 5-2512-14 Years 10-4015-17 Years 5-40Tanner Stage I 2-10Tanner Stage II 5-30Tanner Stage III 10-30Tanner Stage IV 15-40Tanner Stage V 10-40

76

Testosterone, Free Total % Free Free(ng/dL) (%) (pg/mL)

Males 260-1000 1.0-2.7 50-210FemalesPremenopausal 15-70 0.5-1.8 1.0-8.5Postmenopausal 5-51 0.8-1.9 0.6-6.7PediatricMalesCord Blood 17-61 1.7-4.1 3-191-10 Days 187 or Less 0.8-1.7 24 or Less1-3 Months 72-344 0.4-0.8 5-213-5 Months 201 or Less 0.3-1.1 14 or Less5-7 Months 59 or Less 0.4-1.2 4 or Less7-12 Months 16 or Less 0.4-1.2 0.9 or Less1-5 Years 12 or Less 0.3-1.1 0.6 or Less6-9 Years 3-30 0.9-1.7 0.1-3.210-11 Years 5-50 1.0-1.9 0.6-5.712-14 Years 10-572 1.3-3.0 1.4-15615-17 Years 220-800 1.8-2.7 80-159Tanner Stage I 2-23Tanner Stage II 5-70Tanner Stage III 15-280Tanner Stage IV 105-545Tanner Stage V 265-800FemalesCord Blood 16-44 3.1-14.7 2-41-10 Days 24 or Less 0.8-1.6 2.5 or Less1-3 Months 17 or Less 0.4-1.2 1.2 or Less3-5 Months 12 or Less 0.4-0.8 0.8 or Less5-7 Months 13 or Less 0.3-1.1 1.1 or Less7-12 Months 11 or Less 0.3-1.1 0.5 or Less1-5 Years 12 or Less 0.3-1.1 0.6 or Less6-9 Years 2-20 0.9-1.4 0.1-0.910-11 Years 5-25 1.0-1.9 1.0-5.212-14 Years 10-40 1.0-1.9 1.0-5.215-17 Years 5-40 1.0-1.9 1.0-5.2

Total (ng/dL)Tanner Stage I 2-10Tanner Stage II 5-30Tanner Stage III 10-30Tanner Stage IV 15-40Tanner Stage V 10-40

77

Testosterone, Free,Bioavailable, and Total 30741NIncludes Total Testosterone, Calculated Free andBioavailable Testosterone, SHBG and albuminThis test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Methodology:for women and children, extraction, chromatography,RIA and calculation based on SHBG and albumin levels.For men, chemiluminescencePreferred Specimen:2 mL serum (1.1 mL minimum).Reference Range:Testosterone, Total Total (ng/dL)Males 260-1000FemalesPremenopausal 15-70Postmenopausal 5-51 (Without Estrogen Therapy)Pediatric reference ranges for Testosterone, Total, SerumTotal Males (ng/dL)1-5 Years 12 or Less6-9 Years 3-3010-11 Years 5-5012-14 Years 10-57215-17 Years 220-800Total Females (ng/dL)1-5 Years 12 or Less6-9 Years 2-2010-11 Years 5-2512-14 Years 10-4015-17 Years 5-40Testosterone, Free (calculated)Males<18 Years: Reference range not established18 Years or greater: 34-194 pg/mLFemales<18 Years: Reference range not established18 Years or greater: 1-21 pg/mL

78

Testosterone, Bioavailable (calculated)Males<18 Years: Reference range not established18 Years or greater: 84-402 ng/dLFemales<18 Years: Reference range not established18 Years or greater: 3-29 ng/dLSHBGMales 7-50 nmol/LFemales 17-120 nmol/LPediatric Males FemalesPreterm Infants 24-56 nmol/L 14-40 nmol/LTerm Infants 24-54 nmol/L 16-44 nmol/L2-8 Years 29-141 nmol/L 41-137 nmol/L9-14 Years 32-92 nmol/L 15-123 nmol/LAlbumin, Serum0-40 Years: 3.7-5.1 g/dL41-60 Years: 3.5-4.9 g/dL>60 Years: 3.2-4.6 g/dL

Testosterone, Total 29868PThis test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Methodology:For women and children, extraction, chromatography,RIA. For men, chemiluminescence assay.Preferred Specimen:2 mL serum(0.5 mL minimum; pediatric absolute minimum 0.25 mL).

79

Reference Range:Testosterone, Total Total (ng/dL)Males 260-1000FemalesPremenopausal 15-70Postmenopausal 5-51 (Without Estrogen Therapy)Pediatric Males Total (ng/dL)Cord Blood 17-611-10 Days 187 or Less1-3 Months 72-3443-5 Months 201 or Less5-7 Months 59 or Less7-12 Months 16 or Less1-5 Years 12 or Less6-9 Years 3-3010-11 Years 5-5012-14 Years 10-57215-17 Years 220-800Tanner Stage I 2-23Tanner Stage II 5-70Tanner Stage III 15-280Tanner Stage IV 105-545Tanner Stage V 265-800Total Females (ng/dL)Cord Blood 16-441-10 Days 24 or Less1-3 Months 17 or Less3-5 Months 12 or Less5-7 Months 13 or Less7-12 Months 11 or Less1-5 Years 12 or Less6-9 Years 2-2010-11 Years 5-2512-14 Years 10-4015-17 Years 5-40Tanner Stage I 2-10Tanner Stage II 5-30Tanner Stage III 10-30Tanner Stage IV 15-40Tanner Stage V 10-40

80

Testosterone, Urine 29892PIncludes CreatininePreferred Specimen:5 mL urine (2.1 mL minimum).Reference Range:Testosterone, UrineMaless: 20-170 µg/24hrsFemales: 5-38 µg/24hrsTestosterone, UrineMales: 13-110 µg/g creatFemales: 3-47 µg/g creatCreatinine, UrineAge g/24-hours3-8 0.11-0.689-12 0.17-1.4113-17 0.29-1.87Adults 0.63-2.50

Thyroglobulin Panel 380NIncludes Thyroglobulin Antibody.Preferred Specimen:2 mL serum (0.5 mL minimum).Reference Range:< 2 IU/mLIf the sample contains Thyroglobulin Ab of greater than 2IU/mL, the antibody could interfere in the determinationof Thyroglobulin. Please interpret with caution.ThyroglobulinAge ng/mL2-16 Years 2.3-39.6Adults 3.5-56.0

81

Thyroglobulin, RIA 14510XPreferred Specimen:3 mL frozen serum (1 mL minimum).Reference Range:TSH Correlation TG TSHNormal Thyroid 3-40 ng/mL 0.4-4.0 mU/LNormal Thyroid, suppresssedTSH 1.5-20.0 ng/mL <0.2 mU/LPost Lobectomy, suppressedTSH <10.0 ng/mL <0.2 mU/LNear-total Thyroidectomy, suppressedTSH <2.0 ng/mL <0.1 mU/LAthyreotic, TSH stimulated

<1.0 ng/mL >20.0 mU/LGoiter (Thyroid enlargement)

>40.0 ng/mL

Thyroglobulin Antibody 80986PPreferred Specimen:2 mL serum (0.3 mL minimum).Reference Range:< 2 IU/mL

Thyroid Peroxidase Antibody(Anti-TPO) 80994PPreferred Specimen:1 mL serum(0.5 mL minimum; pediatric absolute minimum 0.22 mL).Reference Range:Children and adults: IU/mL: < 2.0 IU/mLThe thyroid microsomal fraction is an impure preparationof the enzyme Thyroid Peroxidase (TPO). TPO is theantigen recognized by anti-thyroid microsomalantibodies (AMA) in 98% of patients with elevated AMA.The Anti-TPO assay is a technically superior and morespecific method for measuring the antibody.

82

Thyroid Stimulating Hormone(TSH) 30163PPreferred Specimen:2 mL serum (0.5 mL minimum).Reference Range:Pediatrics:Prematures, 28-36 Weeks(1st week of life) 0.70-27.00 mU/LCord Blood, >37 Weeks 2.30-13.20 mU/L1-2 days 3.2 - 34.60 mU/L3-4 days 0.7 - 15.40 mU/L2-20 Weeks 1.70- 9.10 mU/L21 Weeks-20 Years 0.70- 6.40 mU/LAdults: 0.40- 5.50 mU/LPregnancy:First Trimester 0.30- 4.50 mU/LSecond Trimester 0.50- 4.60 mU/LThird Trimester 0.80- 5.20 mU/L

Thyroid Stimulating Hormone(TSH) Antibody 53843PPreferred Specimen:1 mL serum (0.1 mL minimum).Reference Range:Negative

Thyrotropin BlockingAntibody 142554PPreferred Specimen:2 mL serum (0.4 mL minimum).Reference Range:Adults: 10 or less %The assay measures the ability of immunoglobulin toinhibit the Cyclic Amp production by TSH in an in vitrobioassay.

83

Thyrotropin ReleasingHormone 30189PPreferred Specimen:2 mL plasma (0.6 mL minimum).Reference Range:< 5 pg/mL

TSI (Thyroid StimulatingImmunoglobulin) 30148PThis test was developed and its performance characteris-tics have been determined by Quest Diagnostics NicholsInstitute. It has not been cleared or approved by the U.S.Food and Drug Administration. The FDA has determinedthat such clearance or approval is not necessary.Performance characteristics refer to the analyticalperformance of the test.Preferred Specimen:1 mL serum (0.2 mL minimum).Reference Range:125 or less % baseline

Vitamin D, 1, 25-Dihydroxy 16493PPreferred Specimen:3 mL serum (1.1 mL minimum).Reference Range:3-17 years: 27-71 pg/mL≥18 years: 15-60 pg/mL

Vitamin D, 25-Hydroxy 19893PPreferred Specimen:1 mL serum (0.5 mL minimum).Reference Range:Adult: 9-54 ng/mLPediatric: 13-67 ng/mL

84

VMA, 24-Hour Urine 3004NPreferred Specimen:10 mL urine (5 mL minimum).Reference Range:

mg/24 hours3-8 years: 2.3 or less9-12 years: 3.4 or less13-17 years: 3.9 or lessAdults: 6.0 or less

85

References

Page 7, ACTH, Plasma 21410PPediatric data from Euro J Endocrin, 1997, 137:635-647.

Page 8, Aldosterone, Serum 17632PPediatric data from J Clin Endocrinol Metab (1992) 75:1491-1496 and J Clin Endocrinol Metab (1989) 69:1133-1136.

Page 9, Alkaline Phosphatase, Bone Specific 17772PPediatric data from Int J Biol Markers (1996) 11:159-164 and JBone Miner Res (1999) 14:1664-1671.

Page 10, 3a-Androstanediol Glucuronide (3-Alpha Diol G)16808PTanner Stage data from J Clin Endocrinol Metab (1991) 72:46-50.

Page 10, Androstenedione, Serum 18549PPediatric data from J Clin Endocrinol Metab (1991)73:674-686and J Clin Endocrinol Metab (1989) 69:1133-1136.

Page 16, Catecholamines, Fractionated, Plasma 8193NPediatric data from J Chromatogr (1993) 617:304-307.

Page 19, Collagen Cross-Linked N-Telopeptide (NTx), Urine9191NPediatric data from Bone (1994) 15:31-34.

Page 20, Corticosterone 21394PPediatric data from J Clin Endocrinol Metab (1992) 75:1491-1496.

Page 20, Cortisol Binding Globulin (Transcortin) 30338PPediatric data from Pediatric Research, 1994, 37:112-116.

Page 21, Cortisol, Serum 11281XPediatric data from J Clin Endocrinol Metab (1991) 73:674- 686and J Clin Endocrinol Metab (1989) 69:1133-1136.

Page 22, Cortisol, Free, Serum or Plasma 21469PNewborn and infant pediatric data from Bio Neonate (1990)57:21-29.

Page 23, Cortisone, Serum 141598PPediatric data from Pediat Res (1980) 14:39-46.

Page 24, Deoxycorticosterone 16568PPediatric data from J Clin Endocrinol Metab (1991) 73:674-686

Page 25, 11-Deoxycortisol (Compound S) 16576PPediatric data from J Clin Endocrinol Metab (1991) 73:674-686and J Clin Endocrinol Metab (1989) 69:1133-1136. Markedelevations of 21 Deoxycortisol (as may occur in 21 Hydroxylasedeficiency) can spuriously increase values for 11 Deoxycortisol.

86

References

Page 26, Deoxypyridinoline (DPD), Free 2279NPediatric data from Scan J Clin Lab Invest (1996) 56:715-719.

Page 27, DHEA (Dehydroepiandrosterone), Serum 21964PPediatric data from J clin Endocrinol Metab (1991) 73:674-686

Page 28, DHEA Sulfate 21915PIncludes data from J Clin Endocrinol Metab (1982) 54:1216-1220 and J Clin Endocrinol Metab (1994) 78:266-270.

Page 29, Dihydrotestosterone 67751PIncludes data from J Clin Endocrinol Metab (1979) 48:821-826

Page 34, Estrone, Serum 22582PPediatric data from Bidlingmaier F, et al. 1973, PediatricResearch 7:901-907.

Page 34, Fructosamine 22947PPediatric data from Ann Clin Biochem (1989) 26:328-331,Archives of Disease in Children (1986) 61:113-117 and ClinChem (1988) 34:2444-2447.

Page 37, Gastrin 23333PPediatric ranges from: Sann, L, et al 1975 Arch Dis Child 50:782and Janik JS, et al 1977 Pediatrics 60:60

Page 37, Glucagon 23382PPediatric data from J of Clin Invest (1974) 53:1159-1166 andPediatr Res (1981) 15:912-915.

Page 38, Growth Hormone (hGH) 29637PWilliams Textbook of Endocrinology, 9th ed., p. 300, 1998.Stewart PM et al, Annals of Clinical Biochemistry, 26:205-206,1989.

Page 39, Growth Hormone Releasing Hormone 141770PPediatric data from Horm Metabol Res (1987) 19:434-436.

Page 44, 18-Hydroxycorticosterone (18-OH-B) 16741PPediatric data from J Clin Endocrinol Metab (1992) 75:1491-1496 and J Clin Endocrinol (1989) 69:1133-1136

Page 45, 18-Hydroxydeoxycorticosterone (18-OH-DOC)112060PPediatric data from Endocrinol Japan (1989) 36:851-858.

Page 46, 17-Hydroxypregnenolone 67652PPediatric data from J Clin Endocrinol Metab (1991) 73:674-686and J Clin Endocrinol Metab (1989) 69:1133-1136

87

References

Page 47, 17-Hydroxyprogesterone 16691PIncludes data from J Clin Endocrinol Metab (1989) 69:577,NEngl J Med(1990) 323:849, J Clin Endocrinol Metab (1990)70:1273,J Clin Endocrinol Metab (1998) 83:3750Includes data from J Clin Metab (1991) 73:674-686 and J ClinEndocrinol Metab (1989) 69:1133-1136 and J Clin EndocrinolMetab (1994) 78:266-270.

Page 56, Leptin 84657NPediatric reference ranges from Clin Endocrinol (1997) 46:727-733

Page 60, Neuron Specific Enolase (NSE) 22251PPediatric data from Clin Chem Lab Med (1998) 36:245-247 andClin Chem (1997) 43:542.

Page 61, Pancreatic Polypeptide 27219PPediatric data from Reprod Nutr Dev (1990)30:65-70, Materia Medica Polona (1989) 21:38-42 and ActaPaediatr Scand (1980) 69:211-214.

Page 62, Plasma Renin Activity 10537NPediatric data from J Pediatrics (1976) 89:256, Pediat Res(1979) 13:817, and Eur J Pediatr (1994) 153:284.

Page 64, Pregnenolone 28373PPediatric data from J Clin Endocrinol Metab (1992) 75:1491-1496

Page 64, Progesterone (Pediatric), Serum 14866XPediatric data from J Clin Endocrinol Metab (1992)

Page 69, Serotonin, Serum 29405PPediatric reference range from Brazilian J Med Biol Res (1993)26:309-317.

Page 70, Sex Hormone Binding Globulin 29421PPediatric data from Clin Endocrinol (1989) 31:201-207 and ActaEndocrinologica (1985) 109:276-280.

Page 74, Testosterone, Free and Total 4960NPediatric data from J Clin Inv (1974) 53:819-828 and J ClinEndocrinol Metab (1973) 36:1132-1142.

Page 77, Testosterone, Free, Bioavailable, and Total 30741NPediatric data from Clin Endocrinol (1989) 31:201-207 and ActaEndocrinologica (1985) 109:276-280.

Page 78, Testosterone, Total 29868PPediatric data from J Clin Inv (1974) 53:819-828 and J ClinEndocrinol Metab (1973) 36:1132-1142.

88

89

Numerical Index

Test Code Test Name Page

380N Thyroglobulin Panel 801024N FSH (Follicle Stimulating Hormone),

Pediatrics 351032N LH, (Luteinizing Hormone) Pediatrics 571248N Homovanillic Acid, 24-Hour Urine 431222N PTH, Intact and Calcium 661818N Estriol, 24-Hour Urine 322279N Deoxypyridinoline (DPD), Free 263004N VMA, 24-Hour Urine 843434N T3, Free, Tracer Dialysis 713533N Estrogen, Total, 24-Hour Urine 333541N Estrone, 24-Hour Urine 333566N Estradiol, 24-Hour Urine 294010N Microalbumin, 24-Hour Urine 594168N Catecholamines, Fractionated,

24-Hour Urine 154960N Testosterone, Free and Total 745140N hCG, Total, Quantitative (Tumor) 406825N Histamine, 24-Hour Urine 417062N Aldosterone, 24-Hour Urine 77716N Pyridinium Collagen Cross-Links,

2-Hour Urine 687625N Pregnanetriol, Urine 638193N Catecholamines, Fractionated, Plasma 168573N C-Peptide, 24-Hour Urine 239191N Collagen Cross-Linked N-Telopeptide

(NTx), Urine 199936N 5-HIAA (5-Hydroxyindoleacetic Acid),

24-Hour Urine 4010046N CAH Panel 11, Neonatal, Random Urine 1110152N PTH, BioIntact (Amino Acids 1-84) and

Calcium 6610275N Insulin Antibody with Reflex to Titer 5110537N Plasma Renin Activity 6210584N GAD/ICA 512/Insulin Antibody Highly

Sensitive 3611178X 18-hydroxycortisol, Free, 24-Hour Urine 4411280X Cortisol, Free, 24-Hour Urine 2211281X Cortisol, Serum 2114510X Thyroglobulin, RIA 8114962X Metanephrines, Fractionated, LC/MS/MS,

24-Hour Urine 5814866X Progesterone (Pediatric), Serum 64

90

Numerical Index

Test Code Test Name Page

15701P Insulin 5016493P Vitamin D, 1, 25-Dihydroxy 8316576P 11-Deoxycortisol (Compound S) 2516568P Deoxycorticosterone 2416691P 17-Hydroxyprogesterone 4716741P 18-Hydroxycorticosterone (18-OH-B) 4416808P 3a-Androstanediol Glucuronide

(3-Alpha Diol G) 1017269P Cyclic Adenosine Monophosphate

(Cyclic AMP), Plasma 2417632P Aldosterone, Serum 817772P Alkaline Phosphatase, Bone Specific 918549P Androstenedione, Serum 1018572P Angiotensin Converting Enzyme (ACE) 1119893P Vitamin D, 25-Hydroxy 8319869P C-Peptide 2319927P Calcitonin 1421113P hCG, Total, Quantitative (Pregnancy) 3921394P Corticosterone 2021410P ACTH, Plasma 721469P Cortisol, Free, Serum or Plasma 2221915P DHEA Sulfate 2821964P DHEA (Dehydroepiandrosterone), Serum 2722251P Neuron Specific Enolase (NSE) 6022517P Estriol, Serum 3222582P Estrone, Serum 3422947P Fructosamine 3423333P Gastrin 3723382P Glucagon 3724158P Histamine, Whole Blood 4224166P Histamine, Plasma 4124786P Inhibin A 5024836P IGF Binding Protein-3 (IGFBP-3) 4924844P IGF-I (Somatomedin-C) 4826922P Osmolality, Serum 6026955P Osmolality, Random Urine 6026971P Osteocalcin, Human

(Bone Gla Protein, BGP) 6127219P Pancreatic Polypeptide 6127292P PTH-Related Protein (PTH-rP) 6628373P Pregnenolone 6428407P Proinsulin 6528423P Prolactin 65

91

Numerical Index

Test Code Test Name Page

29397P Serotonin, Blood 6929405P Serotonin, Serum 6929421P Sex Hormone Binding Globulin 7029637P Growth Hormone (hGH) 3829611P Somatostatin 7029868P Testosterone, Total 7829892P Testosterone, Urine 8030148P TSI (Thyroid Stimulating

Immunoglobulin) 8330171P TBII (Thyrotropin-Binding Inhibitory

Immunoglobulin) 7430163P Thyroid Stimulating Hormone(TSH) 8230189P Thyrotropin Releasing Hormone 8330213P TBG (Thyroxine Binding Globulin) 7430289N Estradiol, Ultrasensitive 3130247P T4, Free, Non-Dialysis 7330262P T4, Total (Thyroxine) 7330338P Cortisol Binding Globulin (Transcortin) 2030510P T3, Free, Non-Dialysis 7130528P T3, Reverse 7130536P T3, Total (Triiodothyronine) 7230741N Testosterone, Free, Bioavailable, and Total 7733753N 17-Ketosteroids, 24-Hour Urine 5334445X Inhibin-B, ELISA 5036954P Insulin, Total (Free and Antibody Bound) 5237924X Microalbumin, Random Urine 5941780N Catecholamines, Fractionated,

Random Urine 1641772N Estradiol, Free 3042093N Parietal Cell Antibody Screen w/Reflex

to Titer 6242218N Growth Hormone Antibody 3842929N 17-Ketosteroids, Fractionated, Urine 5445484P Hemoglobin A1c 4052324P Insulin Antibodies, Highly Sensitive 5153843P Thyroid Stimulating Hormone (TSH)

Antibody 8253967P T3 (Triiodothyronine) Antibody 7060863N Pyridinium Collagen Cross-Links,

24-Hour Urine 6767652P 17-Hydroxypregnenolone 4667751P Dihydrotestosterone 2967934P Prealbumin 63

92

Numerical Index

Test Code Test Name Page

68684P Cyclic Adenosine Monophosphate(Cyclic AMP), Random Urine 24

68924P T4, Free, Direct Dialysis 7269013P Insulin, Free (Bioactive) 5280986P Thyroglobulin Antibody 8180994P Thyroid Peroxidase Antibody (Anti-TPO) 8184657N Leptin 5684665N Tartrate Resistant Acid Phosphatase 7384855N Homovanillic Acid, Random Urine 4386447N Histamine, Random Urine 4286959N Collagen Cross-Linked N-Telopeptide

(NTx), 24-Hour Urine 1886736N Islet Cell Antigen 512 Autoantibodies 5395802P T4 (Thyroxine) Antibody 7298111P Chromogranin A 18

110155P Growth Hormone Binding Protein 39112060P 18-Hydroxydeoxycorticosterone

(18-OH-DOC) 45122499P Renin, Direct 69127225P IGF Binding Protein-1 (IGFBP-1) 48127233P IGF Binding Protein-2 (IGFBP-2) 49127282P Alpha Subunit 9139261P Glutamic Acid Decarboxylase-65

Autoantibodies 38139287P PTH Antibody 65140624P Dexamethasone 26141598P Cortisone, Serum 23141770P Growth Hormone Releasing Hormone 39142554P Thyrotropin Blocking Antibody 82177816P 21-Hydroxylase Antibody 45

93

Alphabetical Index

Test Name Page

Thyroid Stimulating Hormone (TSH) 80ACTH, Plasma 7Aldosterone, 24-Hour Urine 7Aldosterone, Serum 8Alkaline Phosphatase, Bone Specific 9Alpha Subunit 93a-Androstanediol Glucuronide (3-Alpha Diol G) 10Androstenedione, Serum 10Angiotensin Converting Enzyme (ACE) 11CAH Panel 11, Neonatal, Random Urine 11Calcitonin 14Catecholamines, Fractionated, 24-Hour Urine 15Catecholamines, Fractionated, Plasma 16Catecholamines, Fractionated, Random Urine 16Chromogranin A 18Collagen Cross-Linked N-Telopeptide (NTx),

24-Hour Urine 18Collagen Cross-Linked N-Telopeptide (NTx), Urine 19Corticosterone 20Cortisol Binding Globulin (Transcortin) 20Cortisol, Serum 21Cortisol, Free, Serum or Plasma 22Cortisol, Free, 24-Hour Urine 22Cortisone, Serum 23C-Peptide 23C-Peptide, 24-Hour Urine 23Cyclic Adenosine Monophosphate (Cyclic AMP),

Plasma 24Cyclic Adenosine Monophosphate (Cyclic AMP),

Random Urine 24Deoxycorticosterone 2411-Deoxycortisol (Compound S) 25Deoxypyridinoline (DPD), Free 26Dexamethasone 26DHEA (Dehydroepiandrosterone), Serum 27DHEA Sulfate 28Dihydrotestosterone 29Estradiol, 24-Hour Urine 29Estradiol, Free 30Estradiol, Ultrasensitive 31Estriol, 24-Hour Urine 32Estriol, Serum 32Estrogen, Total, 24-Hour Urine 33

94

Alphabetical Index

Test Name Page

Estrone, 24-Hour Urine 33Estrone, Serum 34Fructosamine 34FSH (Follicle Stimulating Hormone), Pediatrics 35GAD/ICA 512/Insulin Antibody Highly Sensitive 36Gastrin 37Glucagon 37Glutamic Acid Decarboxylase-65 Autoantibodies 38Growth Hormone (hGH) 38Growth Hormone Antibody 38Growth Hormone Binding Protein 39Growth Hormone Releasing Hormone 39hCG, Total, Quantitative (Pregnancy) 39hCG, Total, Quantitative (Tumor) 40Hemoglobin A1c 405-HIAA (5-Hydroxyindoleacetic Acid), 24-Hour Urine 40Histamine, 24-Hour Urine 41Histamine, Plasma 41Histamine, Random Urine 42Histamine, Whole Blood 42Homovanillic Acid, 24-Hour Urine 43Homovanillic Acid, Random Urine 4318-Hydroxycorticosterone (18-OH-B) 4418-hydroxycortisol, Free, 24-Hour Urine 4418-Hydroxydeoxycorticosterone (18-OH-DOC) 4521-Hydroxylase Antibody 4517-Hydroxypregnenolone 4617-Hydroxyprogesterone 47IGF-I (Somatomedin-C) 48IGF Binding Protein-1 (IGFBP-1) 48IGF Binding Protein-2 (IGFBP-2) 49IGF Binding Protein-3 (IGFBP-3) 49Inhibin A 50Inhibin-B, ELISA 50Insulin 50Insulin Antibodies, Highly Sensitive 51Insulin Antibody with Reflex to Titer 51Insulin, Free (Bioactive) 52Insulin, Total (Free and Antibody Bound) 52Islet Cell Antigen 512 Autoantibodies 5317-Ketosteroids, 24-Hour Urine 5317-Ketosteroids, Fractionated, Urine 54Leptin 56

95

Alphabetical Index

Test Name Page

LH, (Luteinizing Hormone) Pediatrics 57Metanephrines, Fractionated, LC/MS/MS,

24-Hour Urine 58Microalbumin, 24-Hour Urine 59Microalbumin, Random Urine 59Neuron Specific Enolase (NSE) 60Osmolality, Serum 60Osmolality, Random Urine 60Osteocalcin, Human (Bone Gla Protein, BGP) 61Pancreatic Polypeptide 61Parietal Cell Antibody Screen w/Reflex to Titer 62Plasma Renin Activity 62Prealbumin 63Pregnanetriol, Urine 63Pregnenolone 64Progesterone (Pediatric), Serum 64Proinsulin 65Prolactin 65PTH Antibody 65PTH, BioIntact (Amino Acids 1-84) and Calcium 66PTH, Intact and Calcium 66PTH-Related Protein (PTH-rP) 66Pyridinium Collagen Cross-Links, 24-Hour Urine 67Pyridinium Collagen Cross-Links, 2-Hour Urine 68Renin, Direct 69Serotonin, Blood 69Serotonin, Serum 69Sex Hormone Binding Globulin 70Somatostatin 70T3 (Triiodothyronine) Antibody 70T3, Free, Non-Dialysis 71T3, Free, Tracer Dialysis 71T3, Reverse 71T3, Total (Triiodothyronine) 72T4 (Thyroxine) Antibody 72T4, Free, Direct Dialysis 72T4, Free, Non-Dialysis 73T4, Total (Thyroxine) 73Tartrate Resistant Acid Phosphatase 73TBG (Thyroxine Binding Globulin) 74TBII (Thyrotropin-Binding Inhibitory Immunoglobulin) 74Testosterone, Free and Total 74Testosterone, Free, Bioavailable, and Total 77

96

Alphabetical Index

Test Name Page

Testosterone, Total 78Testosterone, Urine 80Thyroglobulin Panel 80Thyroglobulin, RIA 81Thyroglobulin Antibody 81Thyroid Peroxidase Antibody (Anti-TPO) 81Thyroid Stimulating Hormone (TSH) 82Thyroid Stimulating Hormone (TSH) Antibody 82Thyrotropin Blocking Antibody 82Thyrotropin Releasing Hormone 83TSI (Thyroid Stimulating Immunoglobulin) 83Vitamin D, 1, 25-Dihydroxy 83Vitamin D, 25-Hydroxy 83VMA, 24-Hour Urine 84